<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32271</article-id><article-id pub-id-type="doi">10.7554/eLife.32271</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-97955"><name><surname>Claus</surname><given-names>Jeroen</given-names></name><email>jeroen@phospho.co.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-98460"><name><surname>Patel</surname><given-names>Gargi</given-names></name><email>gargi.patel@bsuh.nhs.uk</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-98463"><name><surname>Autore</surname><given-names>Flavia</given-names></name><email>Flavia.Autore@heptares.com</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-108510"><name><surname>Colomba</surname><given-names>Audrey</given-names></name><email>audrey.colomba@crick.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-98467"><name><surname>Weitsman</surname><given-names>Gregory</given-names></name><email>gregory.weitsman@kcl.ac.uk</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-98464"><name><surname>Soliman</surname><given-names>Tanya N</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4687-629X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-98465"><name><surname>Roberts</surname><given-names>Selene</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3732-0556</contrib-id><email>selene.roberts@stfc.ac.uk</email><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79149"><name><surname>Zanetti-Domingues</surname><given-names>Laura C</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-98466"><name><surname>Hirsch</surname><given-names>Michael</given-names></name><email>michael.hirsch@stfc.ac.uk</email><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-98469"><name><surname>Collu</surname><given-names>Francesca</given-names></name><email>francesca.collu@gmail.com</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-98468"><name><surname>George</surname><given-names>Roger</given-names></name><email>roger.george@crick.ac.uk</email><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-98470"><name><surname>Ortiz-Zapater</surname><given-names>Elena</given-names></name><email>elena.ortiz-zapater@kcl.ac.uk</email><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-98472"><name><surname>Barber</surname><given-names>Paul R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8595-1141</contrib-id><email>p.barber@ucl.ac.uk</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-98471"><name><surname>Vojnovic</surname><given-names>Boris</given-names></name><email>boris.vojnovic@oncology.ox.ac.uk</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-30021"><name><surname>Yarden</surname><given-names>Yosef</given-names></name><email>yosef.yarden@weizmann.ac.il</email><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79150"><name><surname>Martin-Fernandez</surname><given-names>Marisa L</given-names></name><email>marisa.martin-fernandez@stfc.ac.uk</email><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-98462"><name><surname>Cameron</surname><given-names>Angus</given-names></name><email>a.cameron@qmul.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-98461"><name><surname>Fraternali</surname><given-names>Franca</given-names></name><email>franca.fraternali@kcl.ac.uk</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-41742"><name><surname>Ng</surname><given-names>Tony</given-names></name><email>tony.ng@kcl.ac.uk</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-97956"><name><surname>Parker</surname><given-names>Peter J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6218-2933</contrib-id><email>peter.parker@crick.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund15"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Protein Phosphorylation Laboratory</institution><institution>The Francis Crick Institute</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Richard Dimbleby Department of Cancer Research, Randall Division and Division of Cancer Studies</institution><institution>Kings College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Sussex Cancer Centre</institution><institution>Brighton and Sussex University Hospitals</institution><addr-line><named-content content-type="city">Brighton</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Randall Division of Cell &amp; Molecular Biophysics</institution><institution>Kings College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Central Laser Facility, Research Complex at Harwell, Science and Technology Facilities Council</institution><institution>Rutherford Appleton Laboratory</institution><addr-line><named-content content-type="city">Didcot</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">The Structural Biology Science Technology Platform</institution><institution>The Francis Crick Institute</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Department of Asthma, Allergy and Respiratory Science</institution><institution>King’s College London, Guy’s Hospital</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff8"><label>8</label><institution content-type="dept">UCL Cancer Institute</institution><institution>University College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff9"><label>9</label><institution content-type="dept">Department of Oncology</institution><institution>Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff10"><label>10</label><institution content-type="dept">Department of Biological Regulation</institution><institution>Weizmann Institute of Science</institution><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff><aff id="aff11"><label>11</label><institution content-type="dept">Barts Cancer Institute</institution><institution>Queen Mary University of London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff12"><label>12</label><institution content-type="dept">Breast Cancer Now Research Unit, Department of Research Oncology</institution><institution>Guy’s Hospital King’s College London School of Medicine</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff13"><label>13</label><institution content-type="dept">School of Cancer and Pharmaceutical Sciences</institution><institution>King’s College London, Guy’s Campus</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1065"><name><surname>Cravatt</surname><given-names>Benjamin F</given-names></name><role>Reviewing Editor</role><aff id="aff14"><institution>The Scripps Research Institute</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>01</day><month>05</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e32271</elocation-id><history><date date-type="received" iso-8601-date="2017-09-25"><day>25</day><month>09</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2018-03-21"><day>21</day><month>03</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Claus et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Claus et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-32271-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.32271.001</object-id><p>While targeted therapy against HER2 is an effective first-line treatment in HER2<sup>+</sup> breast cancer, acquired resistance remains a clinical challenge. The pseudokinase HER3, heterodimerisation partner of HER2, is widely implicated in the resistance to HER2-mediated therapy. Here, we show that lapatinib, an ATP-competitive inhibitor of HER2, is able to induce proliferation cooperatively with the HER3 ligand neuregulin. This counterintuitive synergy between inhibitor and growth factor depends on their ability to promote atypical HER2-HER3 heterodimerisation. By stabilising a particular HER2 conformer, lapatinib drives HER2-HER3 kinase domain heterocomplex formation. This dimer exists in a head-to-head orientation distinct from the canonical asymmetric active dimer. The associated clustering observed for these dimers predisposes to neuregulin responses, affording a proliferative outcome. Our findings provide mechanistic insights into the liabilities involved in targeting kinases with ATP-competitive inhibitors and highlight the complex role of protein conformation in acquired resistance.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.32271.002</object-id><title>eLife digest</title><p>Around 20% of breast cancers are caused because cells have too many copies of a receptor protein called HER2 on their surface. HER2 is responsible for telling the cell to divide. Cells with too many of these receptors – and breast cancer cells can have up to 1000 times too many – divide uncontrollably. This causes the cancer to grow.</p><p>Several successful anti-cancer drugs, such as Herceptin and Kadcyla, are used in the clinic to block the signals produced by HER2. Other drugs called kinase inhibitors prevent HER2 from building its faulty signals. However, a particular kinase inhibitor called lapatinib was not as successful in clinical trials as the medical community had hoped.</p><p>Kinase inhibitors can have unexpected effects. While they can block specific signals in a cell, they can sometimes also cause new types of signals. Could this be one of the reasons behind the disappointing clinical trial results for lapatinib?</p><p>By performing experiments on breast cancer cells grown in the laboratory, Claus, Patel et al. found that lapatinib can counterintuitively boost the growth of breast cancer cells. This occurs because lapatinib causes HER2 receptors to cluster together like a daisy chain along with another protein receptor of the same family, called HER3. These chains are primed to rapidly respond to a molecule called neuregulin, a growth factor that is commonly associated with breast cancer.</p><p>The results presented by Claus, Patel et al. indicate that a particular subset of breast cancer patients – those whose cancer cells do not increase production of HER3 receptors – might better respond to lapatinib than others. The insights gained into what happens to HER2 when you try to block it should also influence the design of new drugs that target either HER2 or HER3.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>HER2</kwd><kwd>HER3</kwd><kwd>protein kinase</kwd><kwd>pseudokinase</kwd><kwd>kinase inhibitors</kwd><kwd>lapatinib</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/G007160/1</award-id><principal-award-recipient><name><surname>Martin-Fernandez</surname><given-names>Marisa L</given-names></name><name><surname>Parker</surname><given-names>Peter J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/K015591/1</award-id><principal-award-recipient><name><surname>Martin-Fernandez</surname><given-names>Marisa L</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/L01257X/1</award-id><principal-award-recipient><name><surname>Fraternali</surname><given-names>Franca</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/H018409/1</award-id><principal-award-recipient><name><surname>Fraternali</surname><given-names>Franca</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>C1519/A6906</award-id><principal-award-recipient><name><surname>Ng</surname><given-names>Tony</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009853</institution-id><institution>Dimbleby Cancer Care</institution></institution-wrap></funding-source><award-id>Richard Dimbleby Professorship</award-id><principal-award-recipient><name><surname>Ng</surname><given-names>Tony</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>C1519/A10331</award-id><principal-award-recipient><name><surname>Ng</surname><given-names>Tony</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000266</institution-id><institution>Engineering and Physical Sciences Research Council</institution></institution-wrap></funding-source><award-id>C1519/A10331</award-id><principal-award-recipient><name><surname>Ng</surname><given-names>Tony</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000780</institution-id><institution>European Commission</institution></institution-wrap></funding-source><award-id>259881</award-id><principal-award-recipient><name><surname>Ng</surname><given-names>Tony</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>C133/A1812</award-id><principal-award-recipient><name><surname>Ng</surname><given-names>Tony</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>C1519/ A16463</award-id><principal-award-recipient><name><surname>Ng</surname><given-names>Tony</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000266</institution-id><institution>Engineering and Physical Sciences Research Council</institution></institution-wrap></funding-source><award-id>C1519/ A16463</award-id><principal-award-recipient><name><surname>Ng</surname><given-names>Tony</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>C1519/ A16463</award-id><principal-award-recipient><name><surname>Ng</surname><given-names>Tony</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000276</institution-id><institution>Department of Health</institution></institution-wrap></funding-source><award-id>C1519/ A16463</award-id><principal-award-recipient><name><surname>Ng</surname><given-names>Tony</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>Institute core funding</award-id><principal-award-recipient><name><surname>Parker</surname><given-names>Peter J</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution>Barts Cancer Institute</institution></institution-wrap></funding-source><award-id>Institute core funding</award-id><principal-award-recipient><name><surname>Cameron</surname><given-names>Angus</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The clinically approved HER2 inhibitor lapatinib causes HER2 and HER3 kinase domains to dimerise in a non-canonical, symmetric orientation, providing a platform for oligomerisation and predisposing to receptor-driven cell proliferation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases plays a major role in proliferative signalling in a variety of cancers (<xref ref-type="bibr" rid="bib4">Baselga and Swain, 2009</xref>; <xref ref-type="bibr" rid="bib83">Yarden and Pines, 2012</xref>). Apart from EGFR (also known as ErbB1), the family consists of the orphan receptor HER2 (ErbB2), the pseudokinase HER3 (ErbB3), and HER4 (ErbB4). Overexpression of HER2 is an oncogenic driver in approximately 20% of all breast cancers (<xref ref-type="bibr" rid="bib44">Lovekin et al., 1991</xref>; <xref ref-type="bibr" rid="bib56">Owens et al., 2004</xref>; <xref ref-type="bibr" rid="bib72">Slamon et al., 1987</xref>). The high clinical relevance of these receptors has made them a target for directed therapy with both antibodies and small molecule kinase inhibitors. In the case of HER2<sup>+</sup> breast cancer, the monoclonal antibody trastuzumab (Herceptin) and its cytotoxic drug-conjugated derivative trastuzumab-emtansine (Kadcyla), the monoclonal antibody blocking HER2-HER3 dimerisation pertuzumab (Perjeta), and the small molecule kinase inhibitor lapatinib (Tykerb/Tyverb) have been successful in the clinic (<xref ref-type="bibr" rid="bib5">Blackwell et al., 2010</xref>; <xref ref-type="bibr" rid="bib9">Cameron et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Diéras et al., 2017</xref>; <xref ref-type="bibr" rid="bib24">Geyer et al., 2006</xref>; <xref ref-type="bibr" rid="bib37">Krop et al., 2017</xref>; <xref ref-type="bibr" rid="bib14">CLEOPATRA Study Group et al., 2015</xref>; <xref ref-type="bibr" rid="bib21">EMILIA Study Group et al., 2012</xref>).</p><p>While HER2 itself has no known ligand, HER3 binds the growth factor neuregulin (NRG, also known as heregulin or HRG) to induce heterodimerisation and signalling (<xref ref-type="bibr" rid="bib73">Sliwkowski et al., 1994</xref>). HER3 has been implicated in therapeutic resistance to HER2-targeted therapy through a variety of mechanisms, including receptor rephosphorylation, HER3 overexpression and increased NRG production (reviewed in [<xref ref-type="bibr" rid="bib11">Claus et al., 2014</xref>]). In terms of cellular signalling in response to HER-family kinase inhibition, HER3-mediated buffering through the Akt/PKB signalling axis has been shown to be an important factor in therapeutic resistance (<xref ref-type="bibr" rid="bib69">Sergina et al., 2007</xref>).</p><p>The dimerisation of EGFR family members is a fluid process mediated by interaction dynamics in practically every domain of the receptor. For EGFR, the ligand-bound, active dimer shows an upright, back-to-back extracellular domain (ECD) interaction where both receptors have bound ligand, although singly-bound dimers can also occur (<xref ref-type="bibr" rid="bib23">Garrett et al., 2002</xref>; <xref ref-type="bibr" rid="bib43">Liu et al., 2012</xref>; <xref ref-type="bibr" rid="bib53">Ogiso et al., 2002</xref>). Although HER2 has no known ligand, it natively adopts this upright, dimerisation-ready ectodomain conformation (<xref ref-type="bibr" rid="bib23">Garrett et al., 2002</xref>). On the intracellular side, formation of the active kinase domain dimer is critically affected by the conformation of the juxtamembrane domain (JMD) (<xref ref-type="bibr" rid="bib34">Jura et al., 2009a</xref>; <xref ref-type="bibr" rid="bib75">Thiel and Carpenter, 2007</xref>). The kinase domains associate in an asymmetric dimer, which resembles the CDK/cyclin-like asymmetric dimer interface (<xref ref-type="bibr" rid="bib33">Jeffrey et al., 1995</xref>; <xref ref-type="bibr" rid="bib87">Zhang et al., 2006</xref>). In this canonical dimer, one kinase (the ‘activator’) allows the dimerisation partner (the ‘receiver’) to adopt an active conformation and become catalytically active. These various conformations have also been observed in near-complete receptors using negative stain electron microscopy (<xref ref-type="bibr" rid="bib46">Mi et al., 2011</xref>). Of note in these receptor dimer formations was the lack of active, asymmetrical kinase domain interactions when the receptor was bound to the ATP-competitive inhibitor lapatinib (<xref ref-type="bibr" rid="bib46">Mi et al., 2011</xref>). Although these interactions have mainly been described in the context of EGFR homodimerisation, they remain a template for the interactions of the rest of the EGFR family. The conformation of the active kinase domain interaction has been validated for EGFR-HER3 and HER2-HER3 (<xref ref-type="bibr" rid="bib35">Jura et al., 2009b</xref>; <xref ref-type="bibr" rid="bib42">Littlefield et al., 2014</xref>; <xref ref-type="bibr" rid="bib76">van Lengerich et al., 2017</xref>).</p><p>A multitude of studies, using a variety of techniques, have confirmed that EGFR-family receptors can form higher order oligomers, and that the exact nature of these oligomers is modulated by a variety of conditions, including receptor density, ligand presence, ligand type and temperature-dependent membrane behaviour (<xref ref-type="bibr" rid="bib13">Clayton et al., 2005</xref>; <xref ref-type="bibr" rid="bib12">Clayton et al., 2007</xref>; <xref ref-type="bibr" rid="bib28">Huang et al., 2016</xref>; <xref ref-type="bibr" rid="bib49">Nagy et al., 2010</xref>; <xref ref-type="bibr" rid="bib50">Needham et al., 2016</xref>; <xref ref-type="bibr" rid="bib66">Saffarian et al., 2007</xref>; <xref ref-type="bibr" rid="bib76">van Lengerich et al., 2017</xref>; <xref ref-type="bibr" rid="bib82">Yang et al., 2007</xref>; <xref ref-type="bibr" rid="bib86">Zhang et al., 2017</xref>).</p><p>Against the backdrop of such a multitude of association modes, it is clear that conformational dynamics and structural rearrangements are an integral regulator of protein behaviour in the EGFR family.</p><p>We have shown previously that within a kinase, in this case PKCε, occupation of the nucleotide binding pocket with ATP (or an inhibitor) is a major determinant of protein behaviour, conferring the structural stability required for protein–protein interactions to occur and priming sites to be stably phosphorylated (<xref ref-type="bibr" rid="bib8">Cameron et al., 2009</xref>). Similar effects have been observed in several additional kinases, including PKB/Akt, IRE1, and AMPK (<xref ref-type="bibr" rid="bib54">Okuzumi et al., 2009</xref>; <xref ref-type="bibr" rid="bib57">Papa et al., 2003</xref>; <xref ref-type="bibr" rid="bib64">Ross et al., 2017</xref>; <xref ref-type="bibr" rid="bib77">Wang et al., 2012</xref>).</p><p>A notable example of nucleotide binding pocket occupation inducing behaviour independent of catalysis has been described for the RAF family, originally in cRAF, where the inhibitor SB 203580 paradoxically induced activity (<xref ref-type="bibr" rid="bib22">Eyers et al., 1998</xref>). More recently, a similar phenomenon has been shown in BRAF, where the small molecule kinase inhibitor vemurafenib blocks the oncogenic mutant V600E, but stabilises the wild type protein, promoting downstream proliferative signalling (<xref ref-type="bibr" rid="bib26">Hatzivassiliou et al., 2010</xref>; <xref ref-type="bibr" rid="bib45">McKay et al., 2011</xref>; <xref ref-type="bibr" rid="bib61">Poulikakos et al., 2010</xref>; <xref ref-type="bibr" rid="bib74">Thevakumaran et al., 2015</xref>). Within the EGFR family, we and others have shown previously that quinazoline inhibitors can cause homodimer formation of EGFR, and EGFR-MET heterodimerisation, by stabilising particular kinase domain conformers (<xref ref-type="bibr" rid="bib2">Arteaga et al., 1997</xref>; <xref ref-type="bibr" rid="bib7">Bublil et al., 2010</xref>; <xref ref-type="bibr" rid="bib41">Lichtner et al., 2001</xref>; <xref ref-type="bibr" rid="bib55">Ortiz-Zapater et al., 2017</xref>).</p><p>The structural, conformational role that nucleotide pocket occupation can fulfil is particularly interesting in the context of pseudokinases, which have lost their catalytic activity. Sequence analysis shows that many pseudokinases retain several of the conserved residues involved in ATP-binding (<xref ref-type="bibr" rid="bib6">Boudeau et al., 2006</xref>; <xref ref-type="bibr" rid="bib10">Claus et al., 2013</xref>). <italic>In vitro</italic> analysis of the pseudokinome showed that many pseudokinases have nucleotide binding capability (<xref ref-type="bibr" rid="bib48">Murphy et al., 2014</xref>).</p><p>In the case of these ATP-binding pseudokinases, where nucleotide binding does not elicit phosphotransfer, the structural stability conferred by ATP binding may be integral to protein function. This has been observed for the pseudokinase STRAD, which requires ATP binding to sustain a heterotrimeric complex with LKB and MO25 (<xref ref-type="bibr" rid="bib84">Zeqiraj et al., 2009a</xref>; <xref ref-type="bibr" rid="bib85">Zeqiraj et al., 2009b</xref>). Similarly, in the pseudokinase FAM20A ATP-binding, albeit in a non-canonical orientation, is essential for stabilising the FAM20A/FAM20C complex (<xref ref-type="bibr" rid="bib16">Cui et al., 2015</xref>; <xref ref-type="bibr" rid="bib17">Cui et al., 2017</xref>). ATP binding is a structural requirement for the JAK2 JH2 V617F mutant to promote pathogenic signalling (<xref ref-type="bibr" rid="bib25">Hammarén et al., 2015</xref>). In the pseudokinase MLKL, ATP-binding pocket occupation is essential for membrane translocation and its role in necroptotic signalling (<xref ref-type="bibr" rid="bib27">Hildebrand et al., 2014</xref>; <xref ref-type="bibr" rid="bib47">Murphy et al., 2013</xref>).</p><p>HER3 is able to bind ATP (crystallised as PDB ID 3KEX, 3LMG), as well as the Src/ABL inhibitor Bosutinib (PDB ID 4OTW) (<xref ref-type="bibr" rid="bib40">Levinson and Boxer, 2014</xref>; <xref ref-type="bibr" rid="bib18">Davis et al., 2011</xref>; <xref ref-type="bibr" rid="bib35">Jura et al., 2009b</xref>; <xref ref-type="bibr" rid="bib48">Murphy et al., 2014</xref>; <xref ref-type="bibr" rid="bib70">Shi et al., 2010</xref>). Considering the importance of HER3 as a conformational partner in the HER2-HER3 heterodimer, and the established importance of ATP-binding for complex formation in other pseudokinases, the role of nucleotide binding pocket occupation in HER3 function warrants investigation.</p><p>Here, we have integrated the study of kinase-autonomous conformational effects of nucleotide binding pocket occupation with that of HER2-HER3 heterointeraction modalities and downstream proliferative phenotypes in response to drug treatment. We show that nucleotide pocket occupation in both HER2 and the pseudokinase HER3 is of great conformational importance for kinase domain heterodimerisation and subsequent proliferative signalling. In HER2<sup>+</sup> breast cancer cells this leads to an unexpected synergy between the HER3 ligand NRG and the HER2 inhibitor lapatinib, by which their concomitant binding promotes proliferation in 2D and 3D culture systems. Lapatinib is able to promote heterodimerisation between the kinase domains of full-length HER2 and HER3 in cells. However, this dimer interface is different from the canonical active EGFR-family dimer, and it is necessary for the lapatinib/NRG combinatorial proliferative phenotype. Both the lapatinib-induced heterodimer and the cooperative proliferation effects depend strongly on the ability for the pseudokinase HER3 to bind ATP. Consistent with the model, occupying the pseudokinase HER3 with the Src/Abl inhibitor bosutinib stabilises the pseudokinase domain to the extent that it actually promotes HER2-HER3 heterodimerisation and downstream proliferation.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Lapatinib-NRG co-treatment shows a synergistic effect on proliferation, dependent on HER3 ATP binding</title><p>The sensitivity of a variety of oncogene-addicted cell lines to small molecule kinase inhibitors can be counter-acted by the addition of growth factors (<xref ref-type="bibr" rid="bib78">Wilson et al., 2012</xref>). This includes the case of lapatinib-treated HER2<sup>+</sup> breast cancer cell lines, where NRG is seen to mediate a rescue of drug toxicity (<xref ref-type="bibr" rid="bib52">Novotny et al., 2016</xref>; <xref ref-type="bibr" rid="bib78">Wilson et al., 2012</xref>). Using different experimental procedures, we have investigated further these competing effects of lapatinib and NRG on the proliferative behaviour of HER2<sup>+</sup> breast cancer cells.</p><p>In SKBR3, BT474, AU565, and HCC1419 cells treated with a range of lapatinib concentrations for 72 hr, the addition of 10 nM NRG rescues the drug-induced cytotoxicity except at very high drug concentrations (<xref ref-type="fig" rid="fig1">Figure 1a</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a–c</xref>).</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.32271.003</object-id><label>Figure 1.</label><caption><title>Lapatinib and NRG have synergistic effects on SKBR3 growth in 2D and 3D culture systems.</title><p>(<bold>a</bold>) CellTiter-Glo proliferation assay of SKBR3 cells after treatment for 72 hr with a range of lapatinib concentrations ± 10 nM NRG. (<bold>b</bold>) Cell counting assay of SKBR3 cells treated for 72 hr with DMSO or 250 nM lapatinib ±10 nM NRG, before quantification of cell number on a Vi-CELL counter. (<bold>c</bold>) Quantification of SKBR3 3D spheroid area after 8 days of treatment with a range of lapatinib concentrations ± 10 nM NRG, with representative bright field micrographs. Scale bars 0.5 mm. All proliferation data represented as mean ±SEM of three independent experiments each performed in quadruplicate. Corresponding data and statistics available as <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p><p><supplementary-material id="fig1sdata1"><object-id pub-id-type="doi">10.7554/eLife.32271.008</object-id><label>Figure 1—source data 1.</label><caption><title>Numerical data and statistics relating to <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-32271-fig1-data1-v1.pzfx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-32271-fig1-v1"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.32271.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Effects of lapatinib and NRG on breast cancer cell proliferation.</title><p>(<bold>a–f</bold>) BT474, AU565, HCC1419, ZR75, MCF7, and HCC1569 breast cancer cell lines were assayed for proliferation in the response to lapatinib ±10 nM NRG as described in <xref ref-type="fig" rid="fig1">Figure 1a</xref>. BT474 and AU565 represent lapatinib-sensitive lines. HCC1419 and ZR75 represent partially-sensitive lines. MCF7 and HCC1569 represent lapatinib-insensitive lines. (<bold>g</bold>) Western blot analysis of endogenous EGFR family protein levels in SKBR3, BT474, AU565, HCC1419, ZR75, MCF7 and HCC1569 cell lines. (<bold>h–i</bold>) SKBR3 and BT474 cells were treated for 72 hr with a titration of lapatinib ±10 nM EGF, after which proliferation was measured using CellTiter-Glo. (<bold>j</bold>) CellTiter-Glo proliferation assay of SKBR3 cells with transient siRNA knockdown of HER3 using single oligonucleotides. Western blot denotes knockdown efficiency of HER3 si11 and HER3 si13 oligonucleotides. (<bold>k</bold>) CellTiter-Glo endpoint analysis of proliferation of SKBR3 spheroid cultures after 8 days of lapatinib ±NRG. (<bold>l</bold>) Western blot analysis of SKBR3 spheroid cultures in conditions matched to <xref ref-type="fig" rid="fig1">Figure 1c</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1k</xref>. One representative example of three independent experiments is shown. All proliferation data represented as mean ±SEM of three independent experiments each performed in triplicate, except for (<bold>j</bold>), which represents six independent experiments each performed in triplicate. Corresponding data and statistics available as <xref ref-type="supplementary-material" rid="fig1s1sdata1">Figure 1—figure supplement 1—source data 1</xref>.</p><p><supplementary-material id="fig1s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.32271.005</object-id><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Numerical data and statistics relating to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-32271-fig1-figsupp1-data1-v1.pzfx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-32271-fig1-figsupp1-v1"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.32271.006</object-id><label>Figure 1—figure supplement 2.</label><caption><title>The irreversible inhibitor neratinib does not show synergistic growth under ligand co-treatment conditions.</title><p>(<bold>a</bold>) SKBR3 cells were treated for 72 hr with DMSO or 250 nM neratinib ±10 nM NRG, before quantification of cell number on a Vi-CELL counter (<bold>b</bold>) Quantification of spheroid area after 8 days of treatment with a titration of neratinib. Representative bright field micrographs of SKBR3 cell 3D spheroids. Scale bars 0.5 mm. (<bold>c</bold>) CellTiter-Glo endpoint analysis of spheroid cultures from (<bold>b</bold>). (<bold>d</bold>) Western blot analysis of cell signalling in SKBR3 spheroids after 8 days of treatment. All proliferation data represented as mean ±SEM of three independent experiments each performed in triplicate. All western blot shows a representative example of three independent experiments. Corresponding data and statistics available as <xref ref-type="supplementary-material" rid="fig1s2sdata1">Figure 1—figure supplement 2—source data 1</xref>.</p><p><supplementary-material id="fig1s2sdata1"><object-id pub-id-type="doi">10.7554/eLife.32271.007</object-id><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Numerical data and statistics relating to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-32271-fig1-figsupp2-data1-v1.pzfx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-32271-fig1-figsupp2-v1"/></fig></fig-group><p>Interestingly, in the case of the SKBR3, BT474 and AU565 cell lines, low concentrations of lapatinib (~40–400 nM) are able to enhance proliferation in conjunction with 10 nM NRG by 25–30% compared to growth factor alone (<xref ref-type="fig" rid="fig1">Figure 1a</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a–b</xref>). A partial response of this cooperative phenotype is observed in ZR75 and HCC1419 cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1c–d</xref>). This phenotype in SKBR3 cells, while observed previously, has gone unremarked (<xref ref-type="bibr" rid="bib52">Novotny et al., 2016</xref>; <xref ref-type="bibr" rid="bib78">Wilson et al., 2012</xref>). We corroborated our results with a cell counting assay, in which SKBR3 cells were treated for 72 hr with 250 nM lapatinib or vehicle ±10 nM NRG (<xref ref-type="fig" rid="fig1">Figure 1b</xref>). The emergent effect of lapatinib plus NRG depends on lapatinib sensitivity. Two breast cancer cell lines with low lapatinib sensitivity, MCF7 and HCC1569, show low inhibitor-growth factor cooperation (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1e–f</xref>). The growth phenotype in ZR75 may be partially explained by its HER4 expression, considering that NRG is also a ligand for HER4 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1g</xref>).</p><p>Although HER3 has been shown to bind lapatinib <italic>in vitro</italic> with very low affinity (Kd = 5.5 μM) (<xref ref-type="bibr" rid="bib18">Davis et al., 2011</xref>), the synergistic behaviour between lapatinib and NRG occurs in cells at a ~ 50 x lower dose than the <italic>in vitro</italic> Kd, indicating that any binding of lapatinib to HER3 would likely be minor under these conditions. Using a thermal shift assay (TSA), which measures a shift in the thermal stability of a protein after ligand/inhibitor binding <italic>in vitro</italic>, we also show that lapatinib does not strongly bind HER3 as compared to ATP and a panel of other inhibitors (<xref ref-type="fig" rid="fig2">Figure 2a</xref>, see further below).</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.32271.009</object-id><label>Figure 2.</label><caption><title>HER3 ATP-binding pocket occupation is necessary and sufficient to drive SKBR3 cell growth.</title><p>(<bold>a</bold>) <italic>In vitro</italic> TSA binding assay of HER3 with selected kinase inhibitors. (<bold>b</bold>) <italic>In vitro</italic> TSA binding assay of HER2 with lapatinib and bosutinib. (<bold>c</bold>) Quantification of spheroid size after eight days of treatment with a titration of bosutinib with representative bright field micrographs of SKBR3 cell spheroids after eight days of bosutinib treatment. Scale bars signify 0.5 mm. (<bold>d</bold>) Transient co-transfection of MCF7 cells with HER2<sup>wt</sup>-GFP and HER3<sup>wt</sup>-RFP or HER3<sup>KGG</sup>-RFP. Cells were serum starved for one hour, followed by 10 nM NRG or vehicle for ten minutes. HER3 phosphorylation on Y1289 was measured by Western blot and analysed by densitometry relative to total HER3. (<bold>e</bold>) SKBR3 cells were transfected with RFP empty vector, HER3<sup>wt</sup>-RFP, HER3<sup>T787M</sup>-RFP or HER3<sup>KGG</sup>-RFP. 72 hr of bosutinib treatment was initiated 24 hr post-transfection. Proliferation was measured using CellTiter-Glo. TSA data represented as mean ±SEM of (<bold>a</bold>) two independent experiments each performed quadruplicate, or (<bold>b</bold>) three independent experiments each performed in at least quadruplicate. Proliferation data represented as mean ±SEM of three independent experiments each performed in at least triplicate. Western blot data shown as mean ±SD for three independent experiments. Western blot quantifications analysed by one-way ANOVA. ****p≤0.0001 Corresponding data and statistics available as <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>.</p><p><supplementary-material id="fig2sdata1"><object-id pub-id-type="doi">10.7554/eLife.32271.013</object-id><label>Figure 2—source data 1.</label><caption><title>Numerical data and statistics relating to <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-32271-fig2-data1-v1.pzf"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-32271-fig2-v1"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.32271.010</object-id><label>Figure 2—figure supplement 1.</label><caption><title>The effects of HER3 ATP-binding pocket occupation on drug-induced cell proliferation.</title><p>(<bold>a</bold>) TSA of HER3 kinase domain and a titration of bosutinib shows a ΔT<sub>m50</sub> of 4.15 ± 1.94 nM. (<bold>b</bold>) SKBR3 cells were treated with a range of bosutinib concentrations for 72 hr and proliferation was measured using CellTiter-Glo (<bold>c</bold>) CellTiter-Glo endpoint quantification of spheroid cultures from <xref ref-type="fig" rid="fig2">Figure 2b</xref>. (<bold>d</bold>) Western blot analysis of spheroid cultures treated as in (<bold>c</bold>). (<bold>e</bold>) 2D proliferation of SKBR3 cells using a titration of bosutinib ±lapatinib (50 nM or 1 μM) for 72 hr. (<bold>f</bold>) SKBR3 cells were transiently transfected with vector-RFP, HER3<sup>wt</sup>-RFP, or HER3<sup>KGG</sup>-RFP and treated with lapatinib ±10 nM NRG for 72 hr. (<bold>g</bold>) CETSA analysis of bosutinib binding to HER3<sup>wt</sup>, HER3<sup>KGG</sup>, or HER3<sup>T787M</sup>. Lysates of COS7 cells ectopically expressing HER3-RFP were treated with DMSO or 50 nM bosutinib, after which samples were split and matching samples incubated at either 42°C or 50°C. Western blot analysis shows HER3 recovery at 50°C compared to 42°C. Data in (<bold>a-f</bold>) presented as mean ±SEM of three independent experiments each performed in triplicate. Western blot data in (<bold>d</bold>) show a representative example of three independent experiments. Data in (<bold>g</bold>) presented as mean ±SD of four independent experiments. Corresponding data and statistics available as <xref ref-type="supplementary-material" rid="fig2s1sdata1">Figure 2—figure supplement 1—source data 1</xref>.</p><p><supplementary-material id="fig2s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.32271.011</object-id><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Numerical data and statistics relating to <xref ref-type="fig" rid="fig2s1">Figure 2-figure supplement 1</xref>.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-32271-fig2-figsupp1-data1-v1.pzfx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-32271-fig2-figsupp1-v1"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.32271.012</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Cell surface expression of HER3 mutants.</title><p>Flow cytometric analysis of membrane localisation of all HER3-RFP constructs used in this study. Live SKBR3 cells were stained with GFP-conjugated anti-HER3 to show the combination of transfected and endogenous HER3 on the membrane. All HER3-RFP constructs show membrane localisation, as represented by the top right quadrants. Representative flow cytometry plots from one of two independent experiments.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-32271-fig2-figsupp2-v1"/></fig></fig-group><p>While EGF treatment rescued SKBR3 cells from the effects of low-concentration lapatinib treatment, synergistic growth effects such as those observed with lapatinib-NRG co-treatment were not observed for lapatinib-EGF co-treated SKBR3 or BT474 cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1h–i</xref>). Although NRG is also a growth factor ligand for HER4, protein levels of HER4 in SKBR3 cells are very low (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1g</xref>). Additionally, lapatinib is a strong inhibitor of both EGFR and HER4 (<xref ref-type="bibr" rid="bib18">Davis et al., 2011</xref>). Taken together, these data seem to exclude a significant role for EGFR and HER4 in the synergistic growth observed for lapatinib-NRG co-treatment. Moreover, transient knockdown of HER3 with two different siRNA oligonucleotides shows a modest, but consistent reduction in the proliferative effect of ligand-inhibitor co-treatment, implicating HER3 as the relevant growth factor-binding receptor for this NRG response (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1j</xref>).</p><p>The proliferative effects of lapatinib and NRG on SKBR3 cells were also observed in 3D spheroid cultures. As seen in 2D culture systems, in 3D spheroid culture the addition of NRG to lapatinib-treated cells rescues SKBR3 cells from lapatinib-induced cytotoxicity/cytostasis (<xref ref-type="fig" rid="fig1">Figure 1c</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1k–l</xref>). Lapatinib and NRG share a cooperative effect on the induction of proliferation in 3D spheroid cultures, where spheroid size is greater for inhibitor-ligand co-treatment conditions than for those treated with growth factor alone.</p><p>The irreversible inhibitor neratinib binds the same inactive conformation as lapatinib and with similar binding affinity (<xref ref-type="bibr" rid="bib18">Davis et al., 2011</xref>). However, neratinib is an irreversible inhibitor and forms a covalent bond with HER2<sup>C805</sup>, a residue conserved in EGFR and HER4 but not HER3. Neratinib-NRG co-treatment did not show the synergistic proliferative phenotype observed with lapatinib-NRG, in either a cell counting assay, or in 3D spheroid formation (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2a–d</xref>). Similarly, the induction of HER2 and HER3 phosphorylation seen in western blot analysis of lapatinib-NRG co-treated 3D spheroids was absent in neratinib-NRG co-treatment (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1l</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2d</xref>). This indicates that the proliferative phenotype observed for lapatinib is likely to necessitate a dynamic, reversible inhibitor binding.</p><p>Collectively, the data from both 2D and 3D cultures show that there is a counterintuitive synergy between the HER2 inhibitor lapatinib and the HER3 ligand NRG in driving the proliferation of SKBR3 cells. This prompted us to examine the potential for novel allosteric regulation of HER2-HER3 heterotypic interactions by both ligand and inhibitors.</p></sec><sec id="s2-2"><title>HER3 nucleotide pocket occupation is of structural importance</title><p>To study the effects of ATP binding on HER3 function, we aimed to both stabilise and destabilise the pseudokinase nucleotide-binding pocket. This would allow us to investigate the importance of the structural role that nucleotide binding pocket occupation has been shown to play in several (pseudo)kinases.</p><p>To separate the structural and trace catalytic roles that ATP-binding could fulfill in HER3, we used the ATP-competitive Src/Abl inhibitor bosutinib, which has been shown to bind strongly to HER3 but not to other EGFR family members (<xref ref-type="bibr" rid="bib40">Levinson and Boxer, 2014</xref>; <xref ref-type="bibr" rid="bib18">Davis et al., 2011</xref>). We compared bosutinib to a small panel of EGFR family inhibitors as well as an additional Src inhibitor, dasatinib, and measured HER3 thermal stability by TSA (<xref ref-type="fig" rid="fig2">Figure 2a</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a</xref>). In line with previous observations, we confirmed that HER3 strongly binds bosutinib. Significantly, lapatinib was not able to provide a noticeable thermal shift, which corresponds to previously published results indicating HER3 does not bind lapatinib with high affinity (<xref ref-type="bibr" rid="bib18">Davis et al., 2011</xref>). While lapatinib was able to confer strongly increased thermal stability to HER2, bosutinib was not (<xref ref-type="fig" rid="fig2">Figure 2b</xref>). This is in line with previously published data that indicates HER2 is not a strong bosutinib binder (<xref ref-type="bibr" rid="bib18">Davis et al., 2011</xref>).</p><p>We hypothesised that bosutinib might be able to aid proliferation in a cellular context by stabilising the nucleotide binding pocket of HER3 and helping sustain dimer formation, analogous to vemurafenib-bound behaviour of BRAF. In a 2D proliferation assay, SKBR3 cells treated with bosutinib over 72 hr show a dose dependent induction of proliferation without additional NRG stimulation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b</xref>). This proliferative effect is sustained in eight-day treatments in 3D spheroid cultures (<xref ref-type="fig" rid="fig2">Figure 2c</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1d,e</xref>). The ability of bosutinib to induce SKBR3 cell proliferation appears to be an EGFR-family mediated event, as lapatinib treatment can curtail its effects in a dose-dependent manner (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1e</xref>).</p><p>In order to destabilise the HER3 nucleotide binding pocket we made the triple mutant HER3<sup>KGG</sup>. HER3<sup>K742</sup> was mutated to methionine to hinder ATP α-phosphate coordination, which by itself has been shown to reduce HER3 mant-ATP binding affinity (<xref ref-type="bibr" rid="bib70">Shi et al., 2010</xref>). To obstruct ATP binding further, double aspartates were introduced in the glycine-rich loop (HER3<sup>G716D/G718D</sup>) to mimic the pseudokinase-specific aspartate residue observed in the glycine-rich loop of VRK3 (<xref ref-type="bibr" rid="bib68">Scheeff et al., 2009</xref>), adding a negative charge in the area where the ATP phosphates would normally sit. Introduction of this ATP-binding deficient HER3<sup>KGG</sup> mutant into MCF7 cells shows abrogation of ligand-induced trans-phosphorylation of HER3 by HER2 (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). SKBR3 cells ectopically expressing HER3<sup>wt</sup> or HER3<sup>KGG</sup> show a differential proliferative behaviour upon lapatinib ±NRG treatment. This indicates a critical role for HER3 ATP binding in order to sustain inhibitor-growth factor cooperative proliferation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1f</xref>).</p><p>The bosutinib binding of HER3<sup>wt</sup>, HER3<sup>KGG</sup>, and the proposed drug de-sensitised HER3<sup>T787M</sup> (<xref ref-type="bibr" rid="bib40">Levinson and Boxer, 2014</xref>; <xref ref-type="bibr" rid="bib20">Dong et al., 2017</xref>), was investigated using an in-cell thermal shift assay (CETSA) (<xref ref-type="bibr" rid="bib31">Jafari et al., 2014</xref>; <xref ref-type="bibr" rid="bib63">Reinhard et al., 2015</xref>). Where wild type HER3 showed increased thermal stability in cells in the presence of 50 nM bosutinib, HER3<sup>KGG</sup> did not (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1g</xref>). Ectopic expression of wild type HER3, but not HER3<sup>KGG</sup> or HER3<sup>T787M</sup>, enhances bosutinib-mediated proliferation, indicating this behaviour is driven by bosutinib binding to HER3 directly (<xref ref-type="fig" rid="fig2">Figure 2e</xref>). Both HER3<sup>KGG</sup> and HER3<sup>T787M</sup> showed normal localization to the plasma membrane, as measured by flow cytometry, indicating that these mutations did not compromise the receptor and its traffic to the plasma membrane (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p><p>The HER3<sup>KGG</sup> and bosutinib results indicate that nucleotide pocket occupation in HER3 is essential for its ability to sustain a proliferative signalling pathway under distinct circumstances: in the acute response to growth factor, in promoting ligand-inhibitor cooperative proliferation and even after treatment with a HER3-binding inhibitor. This indicates a critical structural role for HER3 ATP-binding pocket occupation in its ability to sustain heterointeractions and proliferation. Considering the proliferative effects observed with the HER3-binding inhibitor bosutinib, our results also suggest that any residual transferase activity HER3 retains does not appear to be important in these responses <italic>in vivo</italic> unless we invoke a hit-and-run mechanism of action for bosutinib on HER3 which would seem unlikely.</p></sec><sec id="s2-3"><title>Lapatinib binding induces HER2-HER3 heterodimerisation</title><p>The stability conferred to a protein kinase by small molecule inhibitor binding has been shown to play an important role in the promotion of protein–protein interactions. We investigated the potential role of lapatinib to similarly promote HER2-HER3 heterodimerisation by stabilising particular protein conformations in HER2 using a FRET-FLIM approach. We measured drug-induced heterodimerisation of HER2 and HER3, as we have done previously in the case of drug-induced dimerisation of the EGF receptor (<xref ref-type="bibr" rid="bib7">Bublil et al., 2010</xref>; <xref ref-type="bibr" rid="bib15">Coban et al., 2015</xref>).</p><p>At endogenous protein levels in SKBR3 cells, we observe lapatinib-driven HER2-HER3 heterodimerisation to levels similar to those seen with NRG (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). Interestingly, the lapatinib-induced dimerisation occurs in the absence of exogenously added NRG, indicating a HER2-HER3 dimer that is driven primarily through intracellular domain interactions. MCF7 cells, which express low levels of endogenous HER2 and HER3 compared to SKBR3, also display lapatinib-induced heterodimerisation of ectopically expressed GFP-HER2<sup>wt</sup> and HA-HER3<sup>wt</sup> (<xref ref-type="fig" rid="fig3">Figure 3b</xref>).</p><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.32271.014</object-id><label>Figure 3.</label><caption><title>Inhibitor-induced HER2-HER3 heterotypic interactions.</title><p>(<bold>a</bold>) FRET-FLIM analysis of endogenous HER2-HER3 association in SKBR3 cells, serum starved for 1 hr, and stimulated with 6.7 nM NRG for 15 min, or inhibited with lapatinib (10 µM) for 1 hr, prior to fixation and staining with IgG anti-HER2-Cy5 and IgG anti-HER3-Alexa546 overnight, at 4°C. (<bold>b</bold>) MCF7 cells were transfected with vectors encoding HER2<sup>wt</sup>-GFP and HER3<sup>wt</sup>-HA. Cells were incubated as in (<bold>a</bold>) and stained with anti-HA antibody conjugated to Alexa-546 (controls treated with vehicle). (<bold>c</bold>) MCF7 cells were transfected with vectors encoding HER2<sup>wt</sup>-GFP and HER3<sup>wt</sup>-HA or HER3<sup>KGG</sup>-HA. Cells treated with lapatinib (10 µM) for 1 hr, prior to fixation and staining with anti-HA antibody conjugated to Alexa-546. (<bold>d</bold>) SKBR3 cells were treated with bosutinib (50 nM, 1 hr), and stained as in (<bold>b</bold>). (<bold>e</bold>, <bold>f</bold>) Molecules/cluster measurements from STORM data taken of SKBR3 cells labelled with HER2Affibody-Alexa488 and HER3Affibody-Alexa647 or NRG-Alexa647 ±14 nM lapatinib or 41 nM bosutinib. Cumulative FRET-FLIM histograms show average FRET efficiency from three independent experiments. **p≤0.01; ****p≤0.0001 Scale bars 5 μm. Clustering data represent mean combination of two independent experiments with each measuring &gt;1000 clusters. Clustering data presented as mean with 95% CI. Corresponding data and statistics available as <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>.</p><p><supplementary-material id="fig3sdata1"><object-id pub-id-type="doi">10.7554/eLife.32271.015</object-id><label>Figure 3—source data 1.</label><caption><title>Numerical data and statistics relating to <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-32271-fig3-data1-v1.pzfx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-32271-fig3-v1"/></fig><p>As discussed above, occupation of the nucleotide binding pocket in HER3 is of importance for its ability to sustain proliferation. This is also reflected in the case of lapatinib-induced heterodimer formation, where the introduction of the nucleotide pocket compromised HER3<sup>KGG</sup> mutant strongly disrupts inhibitor-promoted heterodimerisation (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). In line with the proliferative effects described above, bosutinib was also able to directly promote heterodimerisation between HER2 and HER3 (<xref ref-type="fig" rid="fig3">Figure 3d</xref>).</p><p>Using stochastic optical reconstruction microscopy (STORM), we analysed receptor clustering in SKBR3 cells. Treatment with either NRG, lapatinib, or bosutinib showed a shift in cluster population size compared to control, implying the formation of higher-order oligomers rather than dimers (<xref ref-type="fig" rid="fig3">Figure 3e,f</xref>). The exact HER2-HER3 stoichiometry in these drug-treated oligomers remains elusive, because these experimental conditions allowed us to count only cluster size for either HER2 or HER3, not both at the same time. Therefore, it is expected that the observed HER3 clusters also contain uncounted HER2 receptors, and vice versa, as evident in the FRET-FLIM data.</p></sec><sec id="s2-4"><title>Disruption of the active HER2-HER3 interface</title><p>The active signalling dimer in the EGFR family adopts an asymmetric orientation, in which there is a distinct division of labour in the activator-receiver pairing. One kinase (the activator kinase) does not phosphorylate substrates, but binds in a way that helps its heterodimerisation partner (the receiver kinase) in adopting an active conformation. The receiver kinase is then capable of substrate phosphorylation. Originally described for EGFR homodimerisation, and similar to the cyclin/CDK binding mode (<xref ref-type="bibr" rid="bib33">Jeffrey et al., 1995</xref>; <xref ref-type="bibr" rid="bib87">Zhang et al., 2006</xref>), this canonical active dimerisation interface has been reported across the EGFR family including the heterodimerisation of HER3, which can only perform the activator role (<xref ref-type="bibr" rid="bib35">Jura et al., 2009b</xref>; <xref ref-type="bibr" rid="bib42">Littlefield et al., 2014</xref>; <xref ref-type="bibr" rid="bib76">van Lengerich et al., 2017</xref>). Mutations that disrupt this active interface in both the activator and receiver partner kinases are well-documented and are schematically highlighted (<xref ref-type="fig" rid="fig4">Figure 4a</xref>, <xref ref-type="video" rid="fig4video1">Figure 4—video 1</xref>).</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.32271.016</object-id><label>Figure 4.</label><caption><title>The lapatinib-induced HER2-HER3 dimer is distinct from the active, asymmetric HER2-HER3 dimer orientation.</title><p>(<bold>a</bold>) Schematic representation and molecular model of HER2-HER3 active, asymmetric kinase domain dimer orientation. Inset denotes interaction interface. (<bold>b</bold>) MCF7 cells were transfected with vectors encoding HER2<sup>wt</sup>-GFP or HER2<sup>I714Q</sup>-GFP and HER3<sup>wt</sup>-HA. Cells were treated as described in <xref ref-type="fig" rid="fig3">Figure 3</xref> and HER2-HER3 association was measured by FRET-FLIM. (<bold>c</bold>) MCF7 cells were transfected with vectors encoding HER2-GFP and HER3<sup>wt</sup>-RFP or HER3<sup>V945R</sup>-RFP. Cells were incubated as described above, and treated with DMSO, lapatinib or NRG prior to fixation. Data represents mean ±SEM. *p≤0.05; **p≤0.01, ***p≤0.001; ****p≤0.0001 by one-way ANOVA. Scale bars represent 5 μm. Corresponding data and statistics available as <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>. Molecular model for the interaction in (a) available as <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>.</p><p><supplementary-material id="fig4sdata1"><object-id pub-id-type="doi">10.7554/eLife.32271.020</object-id><label>Figure 4—source data 1.</label><caption><title>Numerical data and statistics relating to <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-32271-fig4-data1-v1.pzfx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><object-id pub-id-type="doi">10.7554/eLife.32271.021</object-id><label>Figure 4—source data 2.</label><caption><title>PDB structure file of molecular interaction model in <xref ref-type="fig" rid="fig4">Figure 4a</xref>.</title></caption><media mime-subtype="x-pdb" mimetype="chemical" xlink:href="elife-32271-fig4-data2-v1.pdb"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-32271-fig4-v1"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.32271.017</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Model of lapatinib binding in HER2 inactive and active conformations shows a potential steric clash.</title><p>(<bold>a</bold>) Lapatinib docking in HER2, with the HER2 active site displayed in the inset. Lapatinib binds the inactive conformation of HER2 where the α-C helix is in the ‘out’ position. E770 and M774 on the HER2 α-C helix highlighted. (<bold>b</bold>) Lapatinib docked into the active conformation of HER2. The α-C helix is in the ‘in’ position, causing a steric clash between E770/M774 and lapatinib. Molecular models for inhibitor docking in (a) and (b) available as <xref ref-type="supplementary-material" rid="fig4s1sdata1">Figure 4—figure supplement 1—source datas 1</xref> and <xref ref-type="supplementary-material" rid="fig4s1sdata2">2</xref>.</p><p><supplementary-material id="fig4s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.32271.018</object-id><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>PDB structure file of inhibitor docking model in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a</xref>.</title></caption><media mime-subtype="x-pdb" mimetype="chemical" xlink:href="elife-32271-fig4-figsupp1-data1-v1.pdb"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><object-id pub-id-type="doi">10.7554/eLife.32271.019</object-id><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>PDB structure file of inhibitor docking model in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1b</xref>.</title></caption><media mime-subtype="x-pdb" mimetype="chemical" xlink:href="elife-32271-fig4-figsupp1-data2-v1.pdb"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-32271-fig4-figsupp1-v1"/></fig><media id="fig4video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-32271-fig4-video1.mp4"><object-id pub-id-type="doi">10.7554/eLife.32271.022</object-id><label>Figure 4—video 1.</label><caption><title>Interface view of the molecular model of an active HER2-HER3 heterodimer, with HER2<sup>I714</sup> and HER3<sup>V945</sup> highlighted.</title></caption></media></fig-group><p>In the case of the active, activator/receiver interface, HER3 buttresses the inward orientation of the HER2 α-C helix, leaving no space for the HER2 α-C helix to adopt the ‘out’ orientation characteristic of the inactive conformation. We modelled the potential effects of HER2 α-C helix positioning on lapatinib binding to test whether canonical activator/receiver orientation (in which the HER2 α-C helix is pushed inwards) would give sufficient space to still accommodate lapatinib. Our modelling showed that, for a HER2 α-C helix in the active, ‘in’ position, lapatinib binding results in a potential steric clash with HER2<sup>E770/M774</sup> (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a,b</xref>). A general decrease of the nucleotide binding pocket volume from 756 Å<sup>3</sup> to 232 Å<sup>3</sup> (calculated using SURFNET v1.5 (<xref ref-type="bibr" rid="bib38">Laskowski, 1995</xref>)) supports these predictions.</p><p>To further test whether the lapatinib-induced HER2-HER3 is adopting the canonical activator/receiver orientation, we used FRET-FLIM to investigate lapatinib-induced dimer formation. The I714Q mutation in HER2, which renders the receptor receiver-impaired, disrupted the lapatinib-driven HER2-HER3 association, indicating it is retained in the lapatinib-induced dimer interface (<xref ref-type="fig" rid="fig4">Figure 4b</xref>). However, the reciprocal activator-impaired mutation in HER3 (HER3<sup>V945R</sup>) did not disrupt lapatinib-mediated heterodimerisation, although it efficiently suppressed the canonical active dimer after ligand-induced heterodimerisation (<xref ref-type="fig" rid="fig4">Figure 4c</xref>).</p><p>It is surmised that the inhibitor binding is able to robustly induce a heterodimer between HER2 and HER3, which is distinct from the canonical active heterodimer induced after growth factor stimulation. The orientation of this non-canonical lapatinib-driven heterodimer retains HER2<sup>I714</sup> in the dimer interface, giving us a starting point for in silico molecular modelling to investigate potential dimer conformations distinct from the well-described active dimer.</p></sec><sec id="s2-5"><title>Lapatinib drives a novel HER2-HER3 heterodimerisation interface</title><p>In the case of type II kinase inhibitors such as lapatinib, the inhibitor stabilises an inactive conformation of the kinase domain, where the α-C helix is tilted outwards. As HER3 lacks the conserved glutamate residue in the α-C helix, HER3<sup>K742</sup> is unable to form the salt bridge normally observed in active kinase domain structures (<xref ref-type="bibr" rid="bib30">Huse and Kuriyan, 2002</xref>). The HER3 ATP-bound conformation therefore does not show a classical active conformation with the α-C helix tilted inward (<xref ref-type="bibr" rid="bib35">Jura et al., 2009b</xref>; <xref ref-type="bibr" rid="bib70">Shi et al., 2010</xref>), but instead resembles the inactive conformation seen in kinases bound to type II inhibitors such as lapatinib. Because lapatinib-bound HER2 and ATP-bound HER3 adopt similar conformations, there is a possibility that the lapatinib-induced, inactive dimer is oriented symmetrically.</p><p>In the crystal lattices of EGFR and HER3 kinase domains, two different symmetrical interaction interfaces have been observed (<xref ref-type="bibr" rid="bib34">Jura et al., 2009a</xref>; <xref ref-type="bibr" rid="bib35">Jura et al., 2009b</xref>). We used molecular modelling to investigate the potential for HER3 and lapatinib-bound HER2 to adopt either of these conformers (<xref ref-type="fig" rid="fig5">Figure 5a–b</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1a–b</xref>). HER2<sup>I714</sup> is present in the interaction interface of both the EGFR-like, staggered orientation, as well as in the head-to-head, HER3-like orientation. This falls in line with the FRET-FLIM data in <xref ref-type="fig" rid="fig4">Figure 4</xref> that suggests the retained presence of the HER2<sup>I714</sup> residue in the lapatinib-induced dimer interface.</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.32271.023</object-id><label>Figure 5.</label><caption><title>The lapatinib-induced HER2-HER3 dimer is in a symmetric orientation.</title><p>(<bold>a</bold>) Lapatinib-bound HER2 (blue, lapatinib in yellow) and ATP analogue-bound HER3 (green, AMP-PNP in pink) were modelled in an EGFR-like symmetric dimer orientation (<xref ref-type="bibr" rid="bib34">Jura et al., 2009a</xref>). Inset highlights the interaction interface. The schematic representation shows active dimer interface residues HER2<sup>I714</sup> and HER3<sup>V945</sup>, as well as the two residues in HER2 unique to this interface for further mutational analysis. (<bold>b</bold>) Lapatinib-bound HER2 in the HER3-like head-to-head symmetric dimer orientation (<xref ref-type="bibr" rid="bib35">Jura et al., 2009b</xref>). Dimer-specific residues are highlighted in the schematic. (<bold>c</bold>) MCF7 cells were transfected with vectors encoding HER2<sup>wt</sup>-GFP, HER2<sup>N764R/K765F</sup>-GFP or HER2<sup>I748R/V750R</sup>-GFP and HER3<sup>wt</sup>-HA. Cells were incubated for 24 hr, and inhibited with 10 µM lapatinib for 1 hr, prior to fixation and staining with anti-HA antibody conjugated to Alexa-546. Data represented as mean ±SEM. ****p≤0.0001, as analysed by one-way ANOVA. Scale bars 5 μm corresponding data and statistics available as <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>. Molecular model for the interactions in (<bold>a</bold>) and (<bold>b</bold>) available as <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref> and <xref ref-type="supplementary-material" rid="fig5sdata3">3</xref>. Residues marking the dimer interface of the lapatinib-induced HER2-HER3 heterodimer, in either the EGFR-like or HER3-like modelled conformations, including the per-residue solvent accessible surface area (in Å<sup>2</sup>) are available as <xref ref-type="supplementary-material" rid="fig5sdata4">Figure 5—source data 4</xref>.</p><p><supplementary-material id="fig5sdata1"><object-id pub-id-type="doi">10.7554/eLife.32271.025</object-id><label>Figure 5—source data 1.</label><caption><title>Numerical data and statistics relating to <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-32271-fig5-data1-v1.pzfx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><object-id pub-id-type="doi">10.7554/eLife.32271.026</object-id><label>Figure 5—source data 2.</label><caption><title>PDB structure file of molecular interaction model in <xref ref-type="fig" rid="fig5">Figure 5a</xref>.</title></caption><media mime-subtype="x-pdb" mimetype="chemical" xlink:href="elife-32271-fig5-data2-v1.pdb"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><object-id pub-id-type="doi">10.7554/eLife.32271.027</object-id><label>Figure 5—source data 3.</label><caption><title>PDB structure file of molecular interaction model in <xref ref-type="fig" rid="fig5">Figure 5b</xref>.</title></caption><media mime-subtype="x-pdb" mimetype="chemical" xlink:href="elife-32271-fig5-data3-v1.pdb"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><object-id pub-id-type="doi">10.7554/eLife.32271.028</object-id><label>Figure 5—source data 4.</label><caption><title>Table with modelled interface residues, including the per-residue solvent-accessible surface area in Å<sup>2</sup>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32271-fig5-data4-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-32271-fig5-v1"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.32271.024</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Molecular models of potential orientations of the lapatinib-induced HER2-HER3 dimer.</title><p>Molecular model of the lapatinib-induced HER2-HER3 dimer in the (<bold>a</bold>) EGFR-like and (<bold>b</bold>) HER3-like orientation with interface residues shown as sticks.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-32271-fig5-figsupp1-v1"/></fig><media id="fig5video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-32271-fig5-video1.mp4"><object-id pub-id-type="doi">10.7554/eLife.32271.029</object-id><label>Figure 5—video 1.</label><caption><title>Interface view of the molecular model of a lapatinib-induced HER2-HER3 heterodimer in the EGFR-like conformation, with HER2<sup>I714</sup> and HER3<sup>V945</sup> highlighted, as well as model-specific interface residues HER2<sup>I748/V750</sup>.</title></caption></media><media id="fig5video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-32271-fig5-video2.mp4"><object-id pub-id-type="doi">10.7554/eLife.32271.030</object-id><label>Figure 5—video 2.</label><caption><title>Interface highlight of the molecular model of a lapatinib-induced HER2-HER3 heterodimer in the HER3-like conformation, with HER2<sup>I714</sup> and HER3<sup>V945</sup> highlighted, as well as model-specific interface residues HER2<sup>N764/K765</sup>.</title></caption></media></fig-group><p>On the basis of these models, we designed pairs of mutations in HER2 that would exclusively disrupt one of the potential heterodimer orientations (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="video" rid="fig5video1">Figure 5—video 1</xref> and <xref ref-type="video" rid="fig5video2">2</xref>). For the EGFR-like, staggered dimer we substituted two hydrophobic residues on HER2 with two positively charged residues, HER2<sup>I748R/V750R</sup>, which should lead to repulsion from the positively charged residues, K998 and K999, lying on the HER3 side of the interface.</p><p>Likewise, for the HER3-like, head-to-head dimer, we predicted that the HER2<sup>N764R/K765F</sup> mutant would disrupt the dimerisation interface. The substitution of an asparagine residue (HER2<sup>N764</sup>) with a positively charged arginine should lead to repulsion from a positively charged HER3 residue (HER3<sup>R702</sup>), lying within a radius of 4 Å and opposite to HER2<sup>N764</sup>, therefore causing severe disruption of the HER3-like dimer interface. Furthermore, the substitution of a lysine residue (HER2<sup>K765</sup>) with a bulky, hydrophobic residue such as phenylalanine should generate clashes at this HER2-HER3 interface.</p><p>These dimer interface mutants were introduced into our FRET-FLIM assay for investigation of the lapatinib-induced heterodimerisation conformer (<xref ref-type="fig" rid="fig5">Figure 5c</xref>). The HER2<sup>N764R/K765F</sup> mutant disrupted heterodimerisation upon lapatinib binding, whereas HER2<sup>I748R/V750R</sup> showed no difference in heterodimer formation. These mutational FRET/FLIM data is consistent with our model that the lapatinib-induced HER2-HER3 heterodimer adopts a symmetrical, head-to-head orientation, similar to the one observed in the HER3 kinase domain crystal lattice (<xref ref-type="bibr" rid="bib35">Jura et al., 2009b</xref>) (<xref ref-type="fig" rid="fig5">Figure 5b</xref>).</p></sec><sec id="s2-6"><title>Head-to-head HER2-HER3 dimerisation is required for inhibitor-induced proliferation</title><p>Having presented modelling and FRET/FLIM data consistent with an orientation of the lapatinib-induced HER2-HER3 dimer being distinct from the active activator/receiver dimer interface, we sought to identify which type of HER2-HER3 interaction caused the NRG-lapatinib co-stimulatory growth observed in 2D proliferation assays.</p><p>In these assays, we did not ectopically introduce the HER2<sup>N764R/K765F</sup> mutant because, firstly, it might also disrupt the active, asymmetrical HER2-HER3 heterodimer interface and secondly, SKBR3 cells have vast numbers of endogenous HER2 receptors that would hinder analysis of the behaviour of ectopically expressed HER2<sup>N764R/K765F</sup>. Instead we identified HER3<sup>L700F</sup> as the reciprocal mutant to HER2<sup>N764R/K765F</sup> (<xref ref-type="fig" rid="fig6">Figure 6a</xref>, <xref ref-type="video" rid="fig6video1">Figure 6—video 1</xref>). We introduced HER3<sup>L700F</sup> into SKBR3 cells to investigate the role of the head-to-head, symmetric dimer interface in the lapatinib-NRG synergistic proliferation described above. While the HER3<sup>V945R</sup> active dimer mutant did not disrupt drug-growth factor cooperative proliferation, the HER3<sup>L700F</sup> mutant did (<xref ref-type="fig" rid="fig6">Figure 6d–e</xref>). Both HER3<sup>L700F</sup> and HER3<sup>V945R</sup> were expressed on the cell surface, as measured by flow cytometry (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Combined, this indicates that the inhibitor-induced heterodimer of HER2 and HER3 is consistent with a head-to-head, symmetrical conformation, and it plays an important role in the synergistic proliferative effects of lapatinib and NRG. Although this conformation has been described from the HER3 kinase domain crystal lattice (<xref ref-type="bibr" rid="bib35">Jura et al., 2009b</xref>), to our knowledge it is the first time a functional role has been ascribed to heterodimers consistent with this interface in cells.</p><fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.32271.031</object-id><label>Figure 6.</label><caption><title>Disruption of the lapatinib-induced dimer inhibits lapatinib-NRG synergistic growth.</title><p>(<bold>a</bold>) Molecular model of the lapatinib-induced HER2-HER3 dimer with the lapatinib-dimer interface residues HER2<sup>N764</sup> and HER2<sup>K765</sup> highlighted (purple), and a potential reciprocal residue HER3<sup>L700F</sup> (cyan). (<bold>b–e</bold>) 2D proliferation assays of SKBR3 cells transfected with (<bold>b</bold>) RFP empty vector, (<bold>c</bold>) HER3<sup>wt</sup>, (<bold>d</bold>) HER3<sup>V945R</sup>, or (<bold>e</bold>) HER3<sup>L700F</sup> and treated with lapatinib ±10 nM NRG as before. Data represents mean ±SEM for six independent experiments, each performed in triplicate. Corresponding data and statistics available as <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>.</p><p><supplementary-material id="fig6sdata1"><object-id pub-id-type="doi">10.7554/eLife.32271.033</object-id><label>Figure 6—source data 1.</label><caption><title>Numerical data and statistics relating to <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-32271-fig6-data1-v1.pzfx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-32271-fig6-v1"/></fig><media id="fig6video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-32271-fig6-video1.mp4"><object-id pub-id-type="doi">10.7554/eLife.32271.032</object-id><label>Figure 6—video 1.</label><caption><title>Interface highlight of the molecular model of a lapatinib-induced HER2-HER3 heterodimer in the HER3-like conformation, with HER2<sup>I714</sup> and HER3<sup>V945</sup> highlighted, as well as model-specific interface residues HER2<sup>N764/K765</sup> and HER3<sup>L700</sup>.</title></caption></media></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The conformational dynamics of HER2-HER3 heterodimerisation are an important consideration for evaluating existing and future targeted therapy intervention strategies against HER2<sup>+</sup> breast cancer and other HER family driven cancers. Here, we show that the HER2 inhibitor lapatinib is paradoxically able to promote proliferative behaviour in HER2<sup>+</sup> breast cancer cells when administered in the presence of the HER3 ligand NRG. The synergy between growth factor and inhibitor requires an intricate, multi-step cascade of conformational events.</p><p>Lapatinib itself is able to promote heterodimerisation between the kinase domains of HER2 and HER3, stabilising an orientation consistent with a symmetric, head-to-head kinase domain heterodimer that is distinct from the canonical, asymmetric, head-to-tail active kinase domain orientation that occurs throughout the EGFR family. An analogous interface has previously been observed in the HER3 kinase domain crystal lattice (<xref ref-type="bibr" rid="bib35">Jura et al., 2009b</xref>); here, we have provided modelling and cellular evidence of a heterodimer with an interface consistent to the one observed in the HER3 kinase domain crystal lattice. Sequestering HER2 and HER3 in these inactive, lapatinib-bound heterodimers was of benefit to NRG-mediated proliferative signalling. Our results, in which inhibitor binding drives dimer formation that boosts signalling and proliferation, shows some parallels with the inhibitor-induced signalling phenotypes in the RAF-family (<xref ref-type="bibr" rid="bib22">Eyers et al., 1998</xref>; <xref ref-type="bibr" rid="bib26">Hatzivassiliou et al., 2010</xref>; <xref ref-type="bibr" rid="bib45">McKay et al., 2011</xref>; <xref ref-type="bibr" rid="bib61">Poulikakos et al., 2010</xref>; <xref ref-type="bibr" rid="bib74">Thevakumaran et al., 2015</xref>)</p><p>While the FRET-FLIM analysis of the lapatinib-induced dimerisation was not able to differentiate between heterodimers or higher order oligomers, our clustering data shows that lapatinib is likely to induce higher order oligomers. Because of the modelled symmetrical nature of these lapatinib-induced dimers, in which both lapatinib-bound HER2 and HER3 would be conformationally available as ‘activator’ receptors for additional oligomerization partners, it is not inconceivable they may act as nucleation points for larger oligomeric signalling platforms. Such signalling arrays, in which mutual cooperativity increases signaling output, have been proposed for EGFR oligomers (<xref ref-type="bibr" rid="bib28">Huang et al., 2016</xref>).</p><p>The addition of ligand potentially causes rearrangements within these platforms through the ligand-induced conformational ballet of multi-level interactions between the various extracellular and intracellular domains of EGFR family receptors (reviewed in (<xref ref-type="bibr" rid="bib39">Lemmon et al., 2014</xref>)). The formation of lapatinib-induced oligomeric platforms may facilitate a transition into active signalling heterodimers upon ligand binding, due to the availability of dimerisation partners in immediate proximity within these drug-induced oligomer platforms.</p><p>Both the lapatinib-induced HER2-HER3 heterodimerisation and the downstream lapatinib-NRG synergistic effects on proliferation depended on the ability of HER3 to bind ATP. Although usually classified as a pseudokinase, HER3 has been shown to retain a measure of autophosphorylation activity (not transphosphorylation) under specific circumstances (<xref ref-type="bibr" rid="bib70">Shi et al., 2010</xref>). We show HER2-HER3 heterodimerisation and downstream proliferative effects can be elicited by the addition of the HER3-binding inhibitor bosutinib, indicating that nucleotide binding pocket occupation performs a structural role that is critical to HER3 function, and apparently independent of any retained catalytic activity. Observing increased heterointeractions and cellular proliferation due to inhibition of an activity-deficient kinase is a strong indication of the importance of ATP-binding in certain pseudokinases, and the necessity of pocket-occupied structural conformers in sustaining protein–protein interactions and subsequent downstream signalling output.</p><p>Because of the importance of HER3 in HER2-targeted therapy resistance, its conserved ATP binding raised the possibility of targeting HER3 with ATP-competitive kinase inhibitors. Our data show, however, that stabilisation of the HER3 kinase domain with an ATP-competitive kinase inhibitor can have a stimulating effect on HER2<sup>+</sup> breast cancer cell proliferation. This indicates that the development of small molecule targeted therapy against HER3 for use in HER2<sup>+</sup> breast cancer needs to be directed away from stabilising the HER3 ATP binding pocket occupied conformer and rather towards stabilising the apo, inactive conformer. An exception to this might be the development of irreversible, adamantane-linked inhibitors of HER3 that target the receptor for proteosomal degradation (<xref ref-type="bibr" rid="bib81">Xie et al., 2014</xref>).</p><p>The substantial effect that lower doses of lapatinib have on proliferation in the presence of growth factor may have an impact on the establishment of lapatinib-resistance <italic>in vivo</italic>. This is in accordance with the observation from xenograft models that resistance occurs much more readily if lapatinib is administered continuously at low doses than if it’s used intermittently at high dose (<xref ref-type="bibr" rid="bib1">Amin et al., 2010</xref>). Increased production of growth factors (including NRG) is a well-described resistance mechanism against HER2-targeted therapy (reviewed in [<xref ref-type="bibr" rid="bib11">Claus et al., 2014</xref>]). NRG production by the microenvironment has also been shown to play a role in metastatic spread of ovarian cancer cells that express high levels of HER3 (<xref ref-type="bibr" rid="bib62">Pradeep et al., 2014</xref>). High expression levels of NRG in HER2<sup>+</sup> breast cancer patients showed a strong correlation with disease recurrence (<xref ref-type="bibr" rid="bib80">Xia et al., 2013</xref>). Several somatic mutations in HER3 observed in cancer fall within the extracellular domain and have a potential effect on ligand-binding affinity (<xref ref-type="bibr" rid="bib32">Jaiswal et al., 2013</xref>). These mutations may exacerbate the inhibitor-growth factor synergistic behaviour reported here.</p><p>Our results provide a potential molecular mechanism for the disappointing results observed in a recent Phase III study of lapatinib used in an adjuvant setting (ALTTO trial) (<xref ref-type="bibr" rid="bib60">Piccart-Gebhart et al., 2016</xref>). The lapatinib-only arm of this study was terminated prematurely, and the effects observed in the adjuvant setting for both lapatinib-trastuzumab co-treatment and trastuzumab treatment followed by lapatinib were not significant. These clinical results indicate there are complicating factors in hindering lapatinib efficacy in patients, which may involve the expression levels of HER3 and NRG stimulation by a complex tumour microenvironment. The complex relationships between distinct protein conformation dynamics, formation of oligomeric assemblies, the availability of ligand, and the various effects on downstream signalling all need to be considered when applying targeted therapy to avoid potentially unexpected enhanced cancer cell proliferation after inhibitor treatment.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Reagents and antibodies</title><p>NRG1 was purchased from PeproTech. Lapatinib was a kind gift from Professor György Kéri (Vichem Chemie Research Ltd Hungary). Bosutinib was purchased from LC Labs. Total HER2, HER3, PKB, HER2 pY877, HER3 pY1289, PKB pS473 and ERK1/2 pT202/pY204 antibodies were purchased from Cell Signaling Technology, anti-α-tubulin from Sigma, total ERK1/2 from Merck, and Alexa Fluor-488 conjugated anti-HER3 antibody from R&amp;D systems.</p></sec><sec id="s4-2"><title>Cell culture and plasmid transfection</title><p>MCF7 and ZR75 cells were cultured in DMEM supplemented with 10% FCS, SKBR3 cells were grown in McCoys medium supplemented with 10% FCS. BT474, AU565, HCC1419, and HCC1569 cells were grown in RPMI with 10% FCS. For BT474 cells 10 μg/ml bovine insulin was included in the culture medium.</p><p>Cells were transfected with plasmid DNA using FuGENE 6, FuGENE HD (Roche), or Lipofectamine LTX (Thermo Fisher Scientific) according to the manufacturer’s protocol.</p><p>All cell lines were sourced from the Francis Crick Institute's Cell Services facility, where they were tested negative for mycoplasma and authenticated via STR profiling.</p></sec><sec id="s4-3"><title>Proliferation assays</title><p>For 2D proliferation assays, cells were plated at 1 × 10<sup>4</sup> cells/well in a 96-well plate. The following day they were subjected to treatment for 72 hr, followed by addition of CellTiter-Glo reagent (Promega) and measured on an EnVision plate reader (Perkin Elmer). CellTiter-Glo data were normalised to the growth factor-null/inhibitor-null untreated control. This caused some growth factor-treated plots to start at above-baseline levels, which is an indication of the proliferative effect that growth factor treatment had in these cells.</p><p>For 3D spheroid assays, 3 × 10<sup>3</sup> cells were plated in a 96-well, round-bottom, ultra-low attachment plate (Corning) in the presence of 1% Matrigel (Corning). After three days of growth, an equal volume of 2x media containing treatment conditions was added and refreshed every three days for a total of eight days of treatment. Phase contrast images were taken using a Zeiss Axiovert 40 CFL microscope with a Zeiss 5x A-plan objective and analysed using ImageJ.</p></sec><sec id="s4-4"><title>Flow cytometry</title><p>SKBR3 cells were transfected with RFP-HER3 mutants for 48 hr. Cells were pre-treated with 0.5 mM EDTA to facilitate removal from the substrate and stained for HER3 extracellular expression using Alexa Fluor-488 conjugated anti-HER3 antibody (R&amp;D systems, clone 66223) as per manufacturer’s instructions. Briefly, cells were blocked using mouse IgG (Santa Cruz Antibodies) for 15 min at room temperature, followed by incubation with conjugated antibody for 30 min at room temperature in the dark. Cells were washed in PBS, 0.5% BSA, 0.1% sodium azide three times before flow cytometric analysis using a BD Fortessa instrument (BD). Results were analysed using the Flo-Jo software.</p></sec><sec id="s4-5"><title>FRET determination by FLIM measurements</title><p>Fluorescence resonance energy transfer (FRET) is used to quantitate direct protein–protein interactions and post-translational modifications. Processing of cells for FRET determination by FLIM has been previously described (<xref ref-type="bibr" rid="bib3">Barber et al., 2009</xref>; <xref ref-type="bibr" rid="bib58">Parsons and Ng, 2002</xref>). FLIM was performed using time-correlated single-photon counting (TCSPC) with a multiphoton microscope system as described previously (<xref ref-type="bibr" rid="bib59">Peter et al., 2005</xref>). For experiments measuring endogenous protein, FRET pairs were Cy5-conjugated anti-HER2 IgG, and Alexa546-conjugated anti-HER3 IgG. For exogenous protein measurements, FRET pairs were HER2-GFP and HER3-HA with an anti-HA IgG, tagged with a Cy3 fluorophore. FRET efficiency between the donor and acceptor bound proteins was calculated with the following equation in each pixel and averaged per cell: FRET eff = 1-tau(DA)/tau(control) where tau(DA) is the lifetime displayed by cells co-expressing the donor and acceptor, whereas tau (control) is the mean donor (GFP) lifetime, measured in the absence of the acceptor.</p></sec><sec id="s4-6"><title>Modelling HER2-HER3 dimers</title><p>We modelled the HER2-HER3 dimer by comparative homology modelling using a multiple templates approach. The active, asymmetric HER2-HER3 dimer was modelled using the crystal structure of the active EGFR kinase domain (PDB ID 2GS2) (<xref ref-type="bibr" rid="bib87">Zhang et al., 2006</xref>) and one chain of the crystal structure of the HER3 homodimer (PDB ID 3KEX) (<xref ref-type="bibr" rid="bib35">Jura et al., 2009b</xref>) as templates. To build the EGFR-like, inactive, symmetric dimer we have used the crystal structure of the EGFR homodimer (PDB ID 3GT8) (<xref ref-type="bibr" rid="bib34">Jura et al., 2009a</xref>), the crystal structure of EGFR complexed with lapatinib (PDB ID 1XKK) (<xref ref-type="bibr" rid="bib79">Wood et al., 2004</xref>) and only one chain of the crystal structure of the HER3 homodimer (PDB ID 3KEX) (<xref ref-type="bibr" rid="bib35">Jura et al., 2009b</xref>). To build the HER3-like dimer, we have used the HER3 homodimer structure (PDB ID 3KEX) (<xref ref-type="bibr" rid="bib35">Jura et al., 2009b</xref>), the crystal structure of EGFR lapatinib-bound (PDB ID 1XKK) (<xref ref-type="bibr" rid="bib79">Wood et al., 2004</xref>) and the crystal structure of the inactive EGFR AMP-PNP bound (PDB ID 2GS7) (<xref ref-type="bibr" rid="bib87">Zhang et al., 2006</xref>). The sequence alignment used to build the model has been created by using PRALINE with the homology-extended alignment strategy (<xref ref-type="bibr" rid="bib71">Simossis et al., 2005</xref>). We generated 200 three-dimensional models using the MODELLER package (<xref ref-type="bibr" rid="bib67">ŠaliSali and Blundell, 1993</xref>). The selected models were chosen on the basis of the MODELLER objective function's DOPE score.</p><p>The volume of the HER2 ATP binding pocket was calculated with the SURFNET 1.5 package (<xref ref-type="bibr" rid="bib38">Laskowski, 1995</xref>), where the cavity regions in a protein are built up by fitting a probe sphere of 1.4 Å<sup>3</sup> into the spaces between atoms.</p><p>The structural alignment was performed using the multi-seq tool of the VMD 1.9.1 package (<xref ref-type="bibr" rid="bib29">Humphrey et al., 1996</xref>), and measurement of interaction surface buried residues was performed using POPScomp (<xref ref-type="bibr" rid="bib36">Kleinjung and Fraternali, 2005</xref>).</p></sec><sec id="s4-7"><title>Receptor clustering assays</title><p>SKBR3 cells were treated with either 14 nM Lapatinib or 41 nM Bosutinib. HER2 and HER3 Affibody ligands were used to label the non-activated states of the receptors (HER2 from Affibody Inc. and plasmid encoding the HER3 affibody was a gift from John Löfblom, protein made in house and shown to bind specifically to HER3 receptors) and NRG-β1 (Peprotech) was used to stimulate the cells. The conjugation of dyes (Invitrogen) to HER2 and HER3 ligands was done in house and the ratio of dye:ligand was confirmed to be ~1:1. The NRG-dye conjugate has been shown to be as active as the unlabelled protein. We incubated cells in 100 nM HER2Affibody-Alexa488 + 50 nM HER3Affibody-Alexa647 or 100 nM HER2Affibody-Alexa488 + 10 nM NRG-Alexa647 ±drug for 1 hr. Cells were chemically fixed using 4% paraformaldehyde (EMS solutions)+0.5% glutaraldehyde (Sigma-Aldrich) diluted into ice-cold PBS.</p><p>Samples were imaged using a Zeiss Elyra super-resolution microscope to stochastically excite the Alexa488 and Alexa647 fluorophores bound to the receptors in the cells and to image single molecules. Imaging was done in TIRF mode using a 100x oil immersion objective lens. We used a 405 nm laser line to aid fluorophore blinking and 488 nm or 640 nm laser lines to excite the fluorophores, alternating the lasers to image the two receptors independently every 300 frames, over a total of ~10,000 frames. The exposure time was 20 ms. A minimum of two replicates of each sample were imaged generating at least 12 regions (25.6 μm x 25.6 μm) covering at least one cell per region. The Zen software localised the single molecule spots in the cells, a threshold was set to discard background spots and the co-ordinates of the positive localisations (typically 30,000 + for HER2 and 5,000 + for HER3 per region) were passed into the Bayesian cluster identification algorithm (<xref ref-type="bibr" rid="bib65">Rubin-Delanchy et al., 2015</xref>)</p><p>The clustering algorithm expects the background and clusters to be uniformly distributed over a rectangular ROI (<xref ref-type="bibr" rid="bib65">Rubin-Delanchy et al., 2015</xref>). The analysed images mainly showed single cells. Of interest are the HER2 and HER3 receptors in the cell membrane, which were visible as a circular shape. In order to conform with the prerequisites of the clustering algorithms, rectangular regions have been manually selected that tightly cover the cell membrane using the most suitable angles (assessed by visual inspection). The whole cell membrane has been covered in this way. The data selected by these regions have been rotated so that the sides of the rectangles became parallel to the coordinate axis. The result was used as input for the clustering algorithm and the algorithm was applied as described by the protocol. The complete lists of molecules per cluster that have been produced by the algorithm were used for the presentation.</p></sec><sec id="s4-8"><title>Recombinant HER3 KD purification</title><p>The baculoviral HER3 kinase domain construct was kindly provided by Prof. Mark Lemmon, University of Pennsylvania. Sf21 cells at 1 × 10<sup>6</sup> cells/ml were infected with P3 virus (7 × 10<sup>7</sup> pfu/ml) at an MOI of 1.0 and allowed to grow for three days. The cells were lysed in lysis buffer containing protease inhibitors, 1 mM DTT and 2 mM BME. The lysate was clarified by centrifugation and incubated with NiNTA resin (Qiagen) for 30 mins at 4°C, after which the resin was washed extensively with buffer containing 50 mM Hepes (pH 7.6), 300 mM NaCl, 2 mM BME, 5% glycerol, 10 mM imidazole. HER3 was eluted in the same buffer with 200 mM imidazole added.</p><p>Each elution was centrifuged at 10,000 rpm to remove any precipitate or resin and applied to a S200 gel filtration column in 50 mM HEPES (pH 7.6), 300 mM NaCl, 2 mM BME, 2.5% glycerol.</p></sec><sec id="s4-9"><title>Thermal shift assay (TSA)</title><p>Thermal shift assays were carried out as described in (<xref ref-type="bibr" rid="bib51">Niesen et al., 2007</xref>). Briefly, in a 96-well RT-PCR plate (Life Technologies) 1 μg HER3 kinase domain/well was incubated with 1 μM inhibitor or 200 μM ATP/10 mM MgCl<sub>2</sub> (as indicated) for 30 mins at 4°C in the presence of Sypro Orange dye (Sigma). HER2 TSA experiments were performed in a 384-well RT-PCR plate (Thermo Fisher Scientific). 0.5 μg of HER2 kinase domain/well was incubated with 1 μM lapatinib, 1 μM bosutinib, or 200 μM ATP/10 mM MgCl<sub>2</sub> for 20 mins at 4°C. HER3 measurements were taken on an Applied Biosystems 7500 Fast Real-Time PCR machine, and HER2 measurements on an Applied Biosystems Quant Studio 7 PCR machine. Data were trimmed and a Boltzmann sigmoidal curve fitted in GraphPad Prism 6. The inflection point of the Boltzmann sigmoidal was taken as the T<sub>m</sub>. Thermal shift ΔT<sub>m</sub> values were obtained by subtracting the T<sub>m</sub> value of the kinase domain alone control.</p></sec><sec id="s4-10"><title>Western blot analysis</title><p>Cells were plated at 0.5 × 10<sup>5</sup> cells/well in 24-well plates. Cells were lysed in 1x sample buffer (containing 1 mM DTT), sonicated and centrifuged. After centrifugation, the lysates were subjected to SDS-PAGE and analyzed by western blotting.</p></sec><sec id="s4-11"><title>Cellular thermal shift assay (CETSA)</title><p>CETSA was performed with COS7 cells transfected with HER3<sup>wt</sup>-RFP, HER3<sup>T787M</sup>-RFP or HER3<sup>KGG</sup>-RFP plasmids as described in (<xref ref-type="bibr" rid="bib31">Jafari et al., 2014</xref>; <xref ref-type="bibr" rid="bib63">Reinhard et al., 2015</xref>). Briefly, COS7 were treated with DMSO or 50 nM bosutinib for 1 hr at 37°C. Cells were washed with PBS, detached and washed again twice with cold PBS. Cell pellets were resuspended in cold PBS with protease inhibitors (Roche) and 100 μl of each cell suspension was transferred into 0.2 ml PCR tubes. PCR tubes were heated for 3 min at 42°C or 50°C in a thermal cycler (DNA Engine DYAD, MJ research, Peltier thermal cycler) and incubated at room temperature for 3 min. Tubes were then immediately transferred onto ice, 35 μl of cold PBS 1.4% NP-40 with protease inhibitors were added and tubes were snap-frozen. Samples were then subjected to two freeze-thaw (at 25°C) cycles and cell lysates were centrifuged at 20,000 g for 1 hr at 4°C. Supernatants were carefully removed and analysed by western blot.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We would like to thank Mark Lemmon for kindly providing HER3 baculoviral constructs. We wish to thank Melanie Keppler for making some of the HER2 mutants used in the experiments; as well as Luis Fernandes for some of the initial HER2-HER3 modelling work. We thank Gilbert Fruwirth for the fluorescent labelling of antibodies for the FRET-FLIM experiments. We thank the Flow Cytometry core facility at the Francis Crick Institute for carrying out the flow cytometry experiments and analysis. This work was supported by Cancer Research UK (C1519/A10331, C133/A1812, and C1519/A6906), the Biotechnology and Biological Sciences Research Council (BB/G007160/1 and BB/H018409/1), Dimbleby Cancer Care, KCL-UCL Comprehensive Cancer Imaging Centre (supported by Cancer Research UK/EPSRC) and in association with the MRC and DoH, The Medical Research Council (MR/L01257X/1 and MR/K015591/1), EU FP7 IMAGINT (EC GRANT: 259881), and the Swiss National Science Foundation.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con11"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con12"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con13"><p>Resources, Software, Methodology</p></fn><fn fn-type="con" id="con14"><p>Resources, Software, Methodology</p></fn><fn fn-type="con" id="con15"><p>Resources, Writing—review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Supervision, Writing—review and editing</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Supervision, Writing—review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Resources, Supervision, Writing—review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Resources, Supervision, Writing—review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Resources, Supervision, Writing—review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.32271.034</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-32271-transrepform-v1.docx"/></supplementary-material></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname> <given-names>DN</given-names></name><name><surname>Sergina</surname> <given-names>N</given-names></name><name><surname>Ahuja</surname> <given-names>D</given-names></name><name><surname>McMahon</surname> <given-names>M</given-names></name><name><surname>Blair</surname> <given-names>JA</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Hann</surname> <given-names>B</given-names></name><name><surname>Koch</surname> <given-names>KM</given-names></name><name><surname>Shokat</surname> <given-names>KM</given-names></name><name><surname>Moasser</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Resiliency and vulnerability in the HER2-HER3 tumorigenic driver</article-title><source>Science Translational Medicine</source><volume>2</volume><elocation-id>16ra7</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3000389</pub-id><pub-id pub-id-type="pmid">20371474</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arteaga</surname> <given-names>CL</given-names></name><name><surname>Ramsey</surname> <given-names>TT</given-names></name><name><surname>Shawver</surname> <given-names>LK</given-names></name><name><surname>Guyer</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site</article-title><source>Journal of Biological Chemistry</source><volume>272</volume><fpage>23247</fpage><lpage>23254</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.37.23247</pub-id><pub-id pub-id-type="pmid">9287333</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname> <given-names>PR</given-names></name><name><surname>Ameer-Beg</surname> <given-names>SM</given-names></name><name><surname>Gilbey</surname> <given-names>J</given-names></name><name><surname>Carlin</surname> <given-names>LM</given-names></name><name><surname>Keppler</surname> <given-names>M</given-names></name><name><surname>Ng</surname> <given-names>TC</given-names></name><name><surname>Vojnovic</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Multiphoton time-domain fluorescence lifetime imaging microscopy: practical application to protein-protein interactions using global analysis</article-title><source>Journal of the Royal Society Interface</source><volume>6</volume><fpage>S93</fpage><lpage>S105</lpage><pub-id pub-id-type="doi">10.1098/rsif.2008.0451.focus</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>Swain</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Novel anticancer targets: revisiting ERBB2 and discovering ERBB3</article-title><source>Nature Reviews Cancer</source><volume>9</volume><fpage>463</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/nrc2656</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackwell</surname> <given-names>KL</given-names></name><name><surname>Burstein</surname> <given-names>HJ</given-names></name><name><surname>Storniolo</surname> <given-names>AM</given-names></name><name><surname>Rugo</surname> <given-names>H</given-names></name><name><surname>Sledge</surname> <given-names>G</given-names></name><name><surname>Koehler</surname> <given-names>M</given-names></name><name><surname>Ellis</surname> <given-names>C</given-names></name><name><surname>Casey</surname> <given-names>M</given-names></name><name><surname>Vukelja</surname> <given-names>S</given-names></name><name><surname>Bischoff</surname> <given-names>J</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>O'Shaughnessy</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer</article-title><source>Journal of Clinical Oncology</source><volume>28</volume><fpage>1124</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.21.4437</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boudeau</surname> <given-names>J</given-names></name><name><surname>Miranda-Saavedra</surname> <given-names>D</given-names></name><name><surname>Barton</surname> <given-names>GJ</given-names></name><name><surname>Alessi</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Emerging roles of pseudokinases</article-title><source>Trends in Cell Biology</source><volume>16</volume><fpage>443</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2006.07.003</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bublil</surname> <given-names>EM</given-names></name><name><surname>Pines</surname> <given-names>G</given-names></name><name><surname>Patel</surname> <given-names>G</given-names></name><name><surname>Fruhwirth</surname> <given-names>G</given-names></name><name><surname>Ng</surname> <given-names>T</given-names></name><name><surname>Yarden</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Kinase-mediated quasi-dimers of EGFR</article-title><source>The FASEB Journal</source><volume>24</volume><fpage>4744</fpage><lpage>4755</lpage><pub-id pub-id-type="doi">10.1096/fj.10-166199</pub-id><pub-id pub-id-type="pmid">20682838</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname> <given-names>AJM</given-names></name><name><surname>Escribano</surname> <given-names>C</given-names></name><name><surname>Saurin</surname> <given-names>AT</given-names></name><name><surname>Kostelecky</surname> <given-names>B</given-names></name><name><surname>Parker</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>16</volume><fpage>624</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1606</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname> <given-names>D</given-names></name><name><surname>Piccart-Gebhart</surname> <given-names>MJ</given-names></name><name><surname>Gelber</surname> <given-names>RD</given-names></name><name><surname>Procter</surname> <given-names>M</given-names></name><name><surname>Goldhirsch</surname> <given-names>A</given-names></name><name><surname>de Azambuja</surname> <given-names>E</given-names></name><name><surname>Castro</surname> <given-names>G</given-names></name><name><surname>Untch</surname> <given-names>M</given-names></name><name><surname>Smith</surname> <given-names>I</given-names></name><name><surname>Gianni</surname> <given-names>L</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>Al-Sakaff</surname> <given-names>N</given-names></name><name><surname>Lauer</surname> <given-names>S</given-names></name><name><surname>McFadden</surname> <given-names>E</given-names></name><name><surname>Leyland-Jones</surname> <given-names>B</given-names></name><name><surname>Bell</surname> <given-names>R</given-names></name><name><surname>Dowsett</surname> <given-names>M</given-names></name><name><surname>Jackisch</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial</article-title><source>The Lancet</source><volume>389</volume><fpage>1195</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)32616-2</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claus</surname> <given-names>J</given-names></name><name><surname>Cameron</surname> <given-names>AJM</given-names></name><name><surname>Parker</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Pseudokinase drug intervention: a potentially poisoned chalice</article-title><source>Biochemical Society Transactions</source><volume>41</volume><fpage>1083</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1042/BST20130078</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claus</surname> <given-names>J</given-names></name><name><surname>Patel</surname> <given-names>G</given-names></name><name><surname>Ng</surname> <given-names>T</given-names></name><name><surname>Parker</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy</article-title><source>Biochemical Society Transactions</source><volume>42</volume><fpage>831</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1042/BST20140043</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clayton</surname> <given-names>AHA</given-names></name><name><surname>Tavarnesi</surname> <given-names>ML</given-names></name><name><surname>Johns</surname> <given-names>TG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Unligated epidermal growth factor receptor forms higher order oligomers within microclusters on A431 cells that are sensitive to tyrosine kinase inhibitor binding</article-title><source>Biochemistry</source><volume>46</volume><fpage>4589</fpage><lpage>4597</lpage><pub-id pub-id-type="doi">10.1021/bi700002b</pub-id><pub-id pub-id-type="pmid">17381163</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clayton</surname> <given-names>AHA</given-names></name><name><surname>Walker</surname> <given-names>F</given-names></name><name><surname>Orchard</surname> <given-names>SG</given-names></name><name><surname>Henderson</surname> <given-names>C</given-names></name><name><surname>Fuchs</surname> <given-names>D</given-names></name><name><surname>Rothacker</surname> <given-names>J</given-names></name><name><surname>Nice</surname> <given-names>EC</given-names></name><name><surname>Burgess</surname> <given-names>AW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis</article-title><source>Journal of Biological Chemistry</source><volume>280</volume><fpage>30392</fpage><lpage>30399</lpage><pub-id pub-id-type="doi">10.1074/jbc.M504770200</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>CLEOPATRA Study Group</collab><name><surname>Swain</surname> <given-names>SM</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>SB</given-names></name><name><surname>Ro</surname> <given-names>J</given-names></name><name><surname>Semiglazov</surname> <given-names>V</given-names></name><name><surname>Campone</surname> <given-names>M</given-names></name><name><surname>Ciruelos</surname> <given-names>E</given-names></name><name><surname>Ferrero</surname> <given-names>JM</given-names></name><name><surname>Schneeweiss</surname> <given-names>A</given-names></name><name><surname>Heeson</surname> <given-names>S</given-names></name><name><surname>Clark</surname> <given-names>E</given-names></name><name><surname>Ross</surname> <given-names>G</given-names></name><name><surname>Benyunes</surname> <given-names>MC</given-names></name><name><surname>Cortés</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer</article-title><source>New England Journal of Medicine</source><volume>372</volume><fpage>724</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1413513</pub-id><pub-id pub-id-type="pmid">25693012</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coban</surname> <given-names>O</given-names></name><name><surname>Zanetti-Dominguez</surname> <given-names>LC</given-names></name><name><surname>Matthews</surname> <given-names>DR</given-names></name><name><surname>Rolfe</surname> <given-names>DJ</given-names></name><name><surname>Weitsman</surname> <given-names>G</given-names></name><name><surname>Barber</surname> <given-names>PR</given-names></name><name><surname>Barbeau</surname> <given-names>J</given-names></name><name><surname>Devauges</surname> <given-names>V</given-names></name><name><surname>Kampmeier</surname> <given-names>F</given-names></name><name><surname>Winn</surname> <given-names>M</given-names></name><name><surname>Vojnovic</surname> <given-names>B</given-names></name><name><surname>Parker</surname> <given-names>PJ</given-names></name><name><surname>Lidke</surname> <given-names>KA</given-names></name><name><surname>Lidke</surname> <given-names>DS</given-names></name><name><surname>Ameer-Beg</surname> <given-names>SM</given-names></name><name><surname>Martin-Fernandez</surname> <given-names>ML</given-names></name><name><surname>Ng</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Effect of phosphorylation on EGFR dimer stability probed by single-molecule dynamics and FRET/FLIM</article-title><source>Biophysical Journal</source><volume>108</volume><fpage>1013</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2015.01.005</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname> <given-names>J</given-names></name><name><surname>Xiao</surname> <given-names>J</given-names></name><name><surname>Tagliabracci</surname> <given-names>VS</given-names></name><name><surname>Wen</surname> <given-names>J</given-names></name><name><surname>Rahdar</surname> <given-names>M</given-names></name><name><surname>Dixon</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A secretory kinase complex regulates extracellular protein phosphorylation</article-title><source>eLife</source><volume>4</volume><elocation-id>e06120</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.06120</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname> <given-names>J</given-names></name><name><surname>Zhu</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Cianfrocco</surname> <given-names>MA</given-names></name><name><surname>Leschziner</surname> <given-names>AE</given-names></name><name><surname>Dixon</surname> <given-names>JE</given-names></name><name><surname>Xiao</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structure of Fam20A reveals a pseudokinase featuring a unique disulfide pattern and inverted ATP-binding</article-title><source>eLife</source><volume>6</volume><elocation-id>e23990</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.23990</pub-id><pub-id pub-id-type="pmid">28432788</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname> <given-names>MI</given-names></name><name><surname>Hunt</surname> <given-names>JP</given-names></name><name><surname>Herrgard</surname> <given-names>S</given-names></name><name><surname>Ciceri</surname> <given-names>P</given-names></name><name><surname>Wodicka</surname> <given-names>LM</given-names></name><name><surname>Pallares</surname> <given-names>G</given-names></name><name><surname>Hocker</surname> <given-names>M</given-names></name><name><surname>Treiber</surname> <given-names>DK</given-names></name><name><surname>Zarrinkar</surname> <given-names>PP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Comprehensive analysis of kinase inhibitor selectivity</article-title><source>Nature Biotechnology</source><volume>29</volume><fpage>1046</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1038/nbt.1990</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diéras</surname> <given-names>V</given-names></name><name><surname>Miles</surname> <given-names>D</given-names></name><name><surname>Verma</surname> <given-names>S</given-names></name><name><surname>Pegram</surname> <given-names>M</given-names></name><name><surname>Welslau</surname> <given-names>M</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>Krop</surname> <given-names>IE</given-names></name><name><surname>Blackwell</surname> <given-names>K</given-names></name><name><surname>Hoersch</surname> <given-names>S</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Green</surname> <given-names>M</given-names></name><name><surname>Gianni</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial</article-title><source>The Lancet Oncology</source><volume>18</volume><fpage>732</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30312-1</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname> <given-names>C-L</given-names></name><name><surname>Guo</surname> <given-names>F-C</given-names></name><name><surname>Xue</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Computational insights into HER3 gatekeeper T768I resistance mutation to bosutinib in HER3-related breast cancer</article-title><source>Medicinal Chemistry Research</source><volume>26</volume><fpage>1926</fpage><lpage>1934</lpage><pub-id pub-id-type="doi">10.1007/s00044-017-1901-2</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>EMILIA Study Group</collab><name><surname>Verma</surname> <given-names>S</given-names></name><name><surname>Miles</surname> <given-names>D</given-names></name><name><surname>Gianni</surname> <given-names>L</given-names></name><name><surname>Krop</surname> <given-names>IE</given-names></name><name><surname>Welslau</surname> <given-names>M</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>Pegram</surname> <given-names>M</given-names></name><name><surname>Oh</surname> <given-names>DY</given-names></name><name><surname>Diéras</surname> <given-names>V</given-names></name><name><surname>Guardino</surname> <given-names>E</given-names></name><name><surname>Fang</surname> <given-names>L</given-names></name><name><surname>Lu</surname> <given-names>MW</given-names></name><name><surname>Olsen</surname> <given-names>S</given-names></name><name><surname>Blackwell</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Trastuzumab emtansine for HER2-positive advanced breast cancer</article-title><source>New England Journal of Medicine</source><volume>367</volume><fpage>1783</fpage><lpage>1791</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1209124</pub-id><pub-id pub-id-type="pmid">23020162</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyers</surname> <given-names>PA</given-names></name><name><surname>Craxton</surname> <given-names>M</given-names></name><name><surname>Morricel</surname> <given-names>N</given-names></name><name><surname>Cohen</surname> <given-names>P</given-names></name><name><surname>Goedert</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution</article-title><source>Chemistry &amp; Biology</source><volume>5</volume><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(98)90170-3</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrett</surname> <given-names>TPJ</given-names></name><name><surname>McKern</surname> <given-names>NM</given-names></name><name><surname>Lou</surname> <given-names>M</given-names></name><name><surname>Elleman</surname> <given-names>TC</given-names></name><name><surname>Adams</surname> <given-names>TE</given-names></name><name><surname>Lovrecz</surname> <given-names>GO</given-names></name><name><surname>Zhu</surname> <given-names>H-J</given-names></name><name><surname>Walker</surname> <given-names>F</given-names></name><name><surname>Frenkel</surname> <given-names>MJ</given-names></name><name><surname>Hoyne</surname> <given-names>PA</given-names></name><name><surname>Jorissen</surname> <given-names>RN</given-names></name><name><surname>Nice</surname> <given-names>EC</given-names></name><name><surname>Burgess</surname> <given-names>AW</given-names></name><name><surname>Ward</surname> <given-names>CW</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α</article-title><source>Cell</source><volume>110</volume><fpage>763</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00940-6</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geyer</surname> <given-names>CE</given-names></name><name><surname>Forster</surname> <given-names>J</given-names></name><name><surname>Lindquist</surname> <given-names>D</given-names></name><name><surname>Chan</surname> <given-names>S</given-names></name><name><surname>Romieu</surname> <given-names>CG</given-names></name><name><surname>Pienkowski</surname> <given-names>T</given-names></name><name><surname>Jagiello-Gruszfeld</surname> <given-names>A</given-names></name><name><surname>Crown</surname> <given-names>J</given-names></name><name><surname>Chan</surname> <given-names>A</given-names></name><name><surname>Kaufman</surname> <given-names>B</given-names></name><name><surname>Skarlos</surname> <given-names>D</given-names></name><name><surname>Campone</surname> <given-names>M</given-names></name><name><surname>Davidson</surname> <given-names>N</given-names></name><name><surname>Berger</surname> <given-names>M</given-names></name><name><surname>Oliva</surname> <given-names>C</given-names></name><name><surname>Rubin</surname> <given-names>SD</given-names></name><name><surname>Stein</surname> <given-names>S</given-names></name><name><surname>Cameron</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Lapatinib plus capecitabine for HER2-positive advanced breast cancer</article-title><source>New England Journal of Medicine</source><volume>355</volume><fpage>2733</fpage><lpage>2743</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa064320</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammarén</surname> <given-names>HM</given-names></name><name><surname>Ungureanu</surname> <given-names>D</given-names></name><name><surname>Grisouard</surname> <given-names>J</given-names></name><name><surname>Skoda</surname> <given-names>RC</given-names></name><name><surname>Hubbard</surname> <given-names>SR</given-names></name><name><surname>Silvennoinen</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation</article-title><source>PNAS</source><volume>112</volume><fpage>4642</fpage><lpage>4647</lpage><pub-id pub-id-type="doi">10.1073/pnas.1423201112</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatzivassiliou</surname> <given-names>G</given-names></name><name><surname>Song</surname> <given-names>K</given-names></name><name><surname>Yen</surname> <given-names>I</given-names></name><name><surname>Brandhuber</surname> <given-names>BJ</given-names></name><name><surname>Anderson</surname> <given-names>DJ</given-names></name><name><surname>Alvarado</surname> <given-names>R</given-names></name><name><surname>Ludlam</surname> <given-names>MJC</given-names></name><name><surname>Stokoe</surname> <given-names>D</given-names></name><name><surname>Gloor</surname> <given-names>SL</given-names></name><name><surname>Vigers</surname> <given-names>G</given-names></name><name><surname>Morales</surname> <given-names>T</given-names></name><name><surname>Aliagas</surname> <given-names>I</given-names></name><name><surname>Liu</surname> <given-names>B</given-names></name><name><surname>Sideris</surname> <given-names>S</given-names></name><name><surname>Hoeflich</surname> <given-names>KP</given-names></name><name><surname>Jaiswal</surname> <given-names>BS</given-names></name><name><surname>Seshagiri</surname> <given-names>S</given-names></name><name><surname>Koeppen</surname> <given-names>H</given-names></name><name><surname>Belvin</surname> <given-names>M</given-names></name><name><surname>Friedman</surname> <given-names>LS</given-names></name><name><surname>Malek</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</article-title><source>Nature</source><volume>464</volume><fpage>431</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1038/nature08833</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hildebrand</surname> <given-names>JM</given-names></name><name><surname>Tanzer</surname> <given-names>MC</given-names></name><name><surname>Lucet</surname> <given-names>IS</given-names></name><name><surname>Young</surname> <given-names>SN</given-names></name><name><surname>Spall</surname> <given-names>SK</given-names></name><name><surname>Sharma</surname> <given-names>P</given-names></name><name><surname>Pierotti</surname> <given-names>C</given-names></name><name><surname>Garnier</surname> <given-names>J-M</given-names></name><name><surname>Dobson</surname> <given-names>RCJ</given-names></name><name><surname>Webb</surname> <given-names>AI</given-names></name><name><surname>Tripaydonis</surname> <given-names>A</given-names></name><name><surname>Babon</surname> <given-names>JJ</given-names></name><name><surname>Mulcair</surname> <given-names>MD</given-names></name><name><surname>Scanlon</surname> <given-names>MJ</given-names></name><name><surname>Alexander</surname> <given-names>WS</given-names></name><name><surname>Wilks</surname> <given-names>AF</given-names></name><name><surname>Czabotar</surname> <given-names>PE</given-names></name><name><surname>Lessene</surname> <given-names>G</given-names></name><name><surname>Murphy</surname> <given-names>JM</given-names></name><name><surname>Silke</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death</article-title><source>PNAS</source><volume>111</volume><fpage>15072</fpage><lpage>15077</lpage><pub-id pub-id-type="doi">10.1073/pnas.1408987111</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>Y</given-names></name><name><surname>Bharill</surname> <given-names>S</given-names></name><name><surname>Karandur</surname> <given-names>D</given-names></name><name><surname>Peterson</surname> <given-names>SM</given-names></name><name><surname>Marita</surname> <given-names>M</given-names></name><name><surname>Shi</surname> <given-names>X</given-names></name><name><surname>Kaliszewski</surname> <given-names>MJ</given-names></name><name><surname>Smith</surname> <given-names>AW</given-names></name><name><surname>Isacoff</surname> <given-names>EY</given-names></name><name><surname>Kuriyan</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Molecular basis for multimerization in the activation of the epidermal growth factor receptor</article-title><source>eLife</source><volume>5</volume><elocation-id>e14107</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.14107</pub-id><pub-id pub-id-type="pmid">27017828</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname> <given-names>W</given-names></name><name><surname>Dalke</surname> <given-names>A</given-names></name><name><surname>Schulten</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>VMD: visual molecular dynamics</article-title><source>Journal of Molecular Graphics</source><volume>14</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/0263-7855(96)00018-5</pub-id><pub-id pub-id-type="pmid">8744570</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huse</surname> <given-names>M</given-names></name><name><surname>Kuriyan</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The conformational plasticity of protein kinases</article-title><source>Cell</source><volume>109</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00741-9</pub-id><pub-id pub-id-type="pmid">12015977</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jafari</surname> <given-names>R</given-names></name><name><surname>Almqvist</surname> <given-names>H</given-names></name><name><surname>Axelsson</surname> <given-names>H</given-names></name><name><surname>Ignatushchenko</surname> <given-names>M</given-names></name><name><surname>Lundbäck</surname> <given-names>T</given-names></name><name><surname>Nordlund</surname> <given-names>P</given-names></name><name><surname>Martinez Molina</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The cellular thermal shift assay for evaluating drug target interactions in cells</article-title><source>Nature Protocols</source><volume>9</volume><fpage>2100</fpage><lpage>2122</lpage><pub-id pub-id-type="doi">10.1038/nprot.2014.138</pub-id><pub-id pub-id-type="pmid">25101824</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaiswal</surname> <given-names>BS</given-names></name><name><surname>Kljavin</surname> <given-names>NM</given-names></name><name><surname>Stawiski</surname> <given-names>EW</given-names></name><name><surname>Chan</surname> <given-names>E</given-names></name><name><surname>Parikh</surname> <given-names>C</given-names></name><name><surname>Durinck</surname> <given-names>S</given-names></name><name><surname>Chaudhuri</surname> <given-names>S</given-names></name><name><surname>Pujara</surname> <given-names>K</given-names></name><name><surname>Guillory</surname> <given-names>J</given-names></name><name><surname>Edgar</surname> <given-names>KA</given-names></name><name><surname>Janakiraman</surname> <given-names>V</given-names></name><name><surname>Scholz</surname> <given-names>RP</given-names></name><name><surname>Bowman</surname> <given-names>KK</given-names></name><name><surname>Lorenzo</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Yuan</surname> <given-names>W</given-names></name><name><surname>Peters</surname> <given-names>BA</given-names></name><name><surname>Kan</surname> <given-names>Z</given-names></name><name><surname>Stinson</surname> <given-names>J</given-names></name><name><surname>Mak</surname> <given-names>M</given-names></name><name><surname>Modrusan</surname> <given-names>Z</given-names></name><name><surname>Eigenbrot</surname> <given-names>C</given-names></name><name><surname>Firestein</surname> <given-names>R</given-names></name><name><surname>Stern</surname> <given-names>HM</given-names></name><name><surname>Rajalingam</surname> <given-names>K</given-names></name><name><surname>Schaefer</surname> <given-names>G</given-names></name><name><surname>Merchant</surname> <given-names>MA</given-names></name><name><surname>Sliwkowski</surname> <given-names>MX</given-names></name><name><surname>de Sauvage</surname> <given-names>FJ</given-names></name><name><surname>Seshagiri</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Oncogenic ERBB3 mutations in human cancers</article-title><source>Cancer Cell</source><volume>23</volume><fpage>603</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.04.012</pub-id><pub-id pub-id-type="pmid">23680147</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeffrey</surname> <given-names>PD</given-names></name><name><surname>Russo</surname> <given-names>AA</given-names></name><name><surname>Polyak</surname> <given-names>K</given-names></name><name><surname>Gibbs</surname> <given-names>E</given-names></name><name><surname>Hurwitz</surname> <given-names>J</given-names></name><name><surname>Massagué</surname> <given-names>J</given-names></name><name><surname>Pavletich</surname> <given-names>NP</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex</article-title><source>Nature</source><volume>376</volume><fpage>313</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1038/376313a0</pub-id><pub-id pub-id-type="pmid">7630397</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jura</surname> <given-names>N</given-names></name><name><surname>Endres</surname> <given-names>NF</given-names></name><name><surname>Engel</surname> <given-names>K</given-names></name><name><surname>Deindl</surname> <given-names>S</given-names></name><name><surname>Das</surname> <given-names>R</given-names></name><name><surname>Lamers</surname> <given-names>MH</given-names></name><name><surname>Wemmer</surname> <given-names>DE</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Kuriyan</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009a</year><article-title>Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment</article-title><source>Cell</source><volume>137</volume><fpage>1293</fpage><lpage>1307</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.04.025</pub-id><pub-id pub-id-type="pmid">19563760</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jura</surname> <given-names>N</given-names></name><name><surname>Shan</surname> <given-names>Y</given-names></name><name><surname>Cao</surname> <given-names>X</given-names></name><name><surname>Shaw</surname> <given-names>DE</given-names></name><name><surname>Kuriyan</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009b</year><article-title>Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3</article-title><source>PNAS</source><volume>106</volume><fpage>21608</fpage><lpage>21613</lpage><pub-id pub-id-type="doi">10.1073/pnas.0912101106</pub-id><pub-id pub-id-type="pmid">20007378</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinjung</surname> <given-names>J</given-names></name><name><surname>Fraternali</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>POPSCOMP: an automated interaction analysis of biomolecular complexes</article-title><source>Nucleic Acids Research</source><volume>33</volume><fpage>W342</fpage><lpage>W346</lpage><pub-id pub-id-type="doi">10.1093/nar/gki369</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krop</surname> <given-names>IE</given-names></name><name><surname>Kim</surname> <given-names>S-B</given-names></name><name><surname>Martin</surname> <given-names>AG</given-names></name><name><surname>LoRusso</surname> <given-names>PM</given-names></name><name><surname>Ferrero</surname> <given-names>J-M</given-names></name><name><surname>Badovinac-Crnjevic</surname> <given-names>T</given-names></name><name><surname>Hoersch</surname> <given-names>S</given-names></name><name><surname>Smitt</surname> <given-names>M</given-names></name><name><surname>Wildiers</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial</article-title><source>The Lancet Oncology</source><volume>18</volume><fpage>743</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30313-3</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laskowski</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>SURFNET: A program for visualizing molecular surfaces, cavities, and intermolecular interactions</article-title><source>Journal of Molecular Graphics</source><volume>13</volume><fpage>323</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/0263-7855(95)00073-9</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemmon</surname> <given-names>MA</given-names></name><name><surname>Schlessinger</surname> <given-names>J</given-names></name><name><surname>Ferguson</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The EGFR family: not so prototypical receptor tyrosine kinases</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>6</volume><elocation-id>a020768</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a020768</pub-id><pub-id pub-id-type="pmid">24691965</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levinson</surname> <given-names>NM</given-names></name><name><surname>Boxer</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>a conserved water-mediated hydrogen bond network defines bosutinib’s kinase selectivity</article-title><source>Nature Chemical Biology</source><volume>10</volume><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1404</pub-id><pub-id pub-id-type="pmid">24292070</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichtner</surname> <given-names>RB</given-names></name><name><surname>Menrad</surname> <given-names>A</given-names></name><name><surname>Sommer</surname> <given-names>A</given-names></name><name><surname>Klar</surname> <given-names>U</given-names></name><name><surname>Schneider</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors</article-title><source>Cancer research</source><volume>61</volume><fpage>5790</fpage><lpage>5795</lpage></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Littlefield</surname> <given-names>P</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Mysore</surname> <given-names>V</given-names></name><name><surname>Shan</surname> <given-names>Y</given-names></name><name><surname>Shaw</surname> <given-names>DE</given-names></name><name><surname>Jura</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations</article-title><source>Science Signaling</source><volume>7</volume><elocation-id>ra114</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2005786</pub-id><pub-id pub-id-type="pmid">25468994</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>P</given-names></name><name><surname>Cleveland</surname> <given-names>TE</given-names></name><name><surname>Bouyain</surname> <given-names>S</given-names></name><name><surname>Byrne</surname> <given-names>PO</given-names></name><name><surname>Longo</surname> <given-names>PA</given-names></name><name><surname>Leahy</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A single ligand is sufficient to activate EGFR dimers</article-title><source>PNAS</source><volume>109</volume><fpage>10861</fpage><lpage>10866</lpage><pub-id pub-id-type="doi">10.1073/pnas.1201114109</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovekin</surname> <given-names>C</given-names></name><name><surname>Ellis</surname> <given-names>IO</given-names></name><name><surname>Locker</surname> <given-names>A</given-names></name><name><surname>Robertson</surname> <given-names>JFR</given-names></name><name><surname>Bell</surname> <given-names>J</given-names></name><name><surname>Nicholson</surname> <given-names>R</given-names></name><name><surname>Gullick</surname> <given-names>WJ</given-names></name><name><surname>Elston</surname> <given-names>CW</given-names></name><name><surname>Blamey</surname> <given-names>RW</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>c-erbB-2 oncoprotein expression in primary and advanced breast cancer</article-title><source>British Journal of Cancer</source><volume>63</volume><elocation-id>439</elocation-id><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/bjc.1991.101</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKay</surname> <given-names>MM</given-names></name><name><surname>Ritt</surname> <given-names>DA</given-names></name><name><surname>Morrison</surname> <given-names>DK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>RAF Inhibitor-Induced KSR1/B-RAF Binding and Its Effects on ERK Cascade Signaling</article-title><source>Current Biology</source><volume>21</volume><fpage>563</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2011.02.033</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mi</surname> <given-names>L-Z</given-names></name><name><surname>Lu</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Nishida</surname> <given-names>N</given-names></name><name><surname>Walz</surname> <given-names>T</given-names></name><name><surname>Springer</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>18</volume><fpage>984</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2092</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname> <given-names>JM</given-names></name><name><surname>Czabotar</surname> <given-names>PE</given-names></name><name><surname>Hildebrand</surname> <given-names>JM</given-names></name><name><surname>Lucet</surname> <given-names>IS</given-names></name><name><surname>Zhang</surname> <given-names>J-G</given-names></name><name><surname>Alvarez-Diaz</surname> <given-names>S</given-names></name><name><surname>Lewis</surname> <given-names>R</given-names></name><name><surname>Lalaoui</surname> <given-names>N</given-names></name><name><surname>Metcalf</surname> <given-names>D</given-names></name><name><surname>Webb</surname> <given-names>AI</given-names></name><name><surname>Young</surname> <given-names>SN</given-names></name><name><surname>Varghese</surname> <given-names>LN</given-names></name><name><surname>Tannahill</surname> <given-names>GM</given-names></name><name><surname>Hatchell</surname> <given-names>EC</given-names></name><name><surname>Majewski</surname> <given-names>IJ</given-names></name><name><surname>Okamoto</surname> <given-names>T</given-names></name><name><surname>Dobson</surname> <given-names>RCJ</given-names></name><name><surname>Hilton</surname> <given-names>DJ</given-names></name><name><surname>Babon</surname> <given-names>JJ</given-names></name><name><surname>Nicola</surname> <given-names>NA</given-names></name><name><surname>Strasser</surname> <given-names>A</given-names></name><name><surname>Silke</surname> <given-names>J</given-names></name><name><surname>Alexander</surname> <given-names>WS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism</article-title><source>Immunity</source><volume>39</volume><fpage>443</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.06.018</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname> <given-names>JM</given-names></name><name><surname>Zhang</surname> <given-names>Q</given-names></name><name><surname>Young</surname> <given-names>SN</given-names></name><name><surname>Reese</surname> <given-names>ML</given-names></name><name><surname>Bailey</surname> <given-names>FP</given-names></name><name><surname>Eyers</surname> <given-names>PA</given-names></name><name><surname>Ungureanu</surname> <given-names>D</given-names></name><name><surname>Hammaren</surname> <given-names>H</given-names></name><name><surname>Silvennoinen</surname> <given-names>O</given-names></name><name><surname>Varghese</surname> <given-names>LN</given-names></name><name><surname>Chen</surname> <given-names>K</given-names></name><name><surname>Tripaydonis</surname> <given-names>A</given-names></name><name><surname>Jura</surname> <given-names>N</given-names></name><name><surname>Fukuda</surname> <given-names>K</given-names></name><name><surname>Qin</surname> <given-names>J</given-names></name><name><surname>Nimchuk</surname> <given-names>Z</given-names></name><name><surname>Mudgett</surname> <given-names>MB</given-names></name><name><surname>Elowe</surname> <given-names>S</given-names></name><name><surname>Gee</surname> <given-names>CL</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Daly</surname> <given-names>RJ</given-names></name><name><surname>Manning</surname> <given-names>G</given-names></name><name><surname>Babon</surname> <given-names>JJ</given-names></name><name><surname>Lucet</surname> <given-names>IS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties</article-title><source>Biochemical Journal</source><volume>457</volume><fpage>323</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1042/BJ20131174</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname> <given-names>P</given-names></name><name><surname>Claus</surname> <given-names>J</given-names></name><name><surname>Jovin</surname> <given-names>TM</given-names></name><name><surname>Arndt-Jovin</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis</article-title><source>PNAS</source><volume>107</volume><fpage>16524</fpage><lpage>16529</lpage><pub-id pub-id-type="doi">10.1073/pnas.1002642107</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Needham</surname> <given-names>SR</given-names></name><name><surname>Roberts</surname> <given-names>SK</given-names></name><name><surname>Arkhipov</surname> <given-names>A</given-names></name><name><surname>Mysore</surname> <given-names>VP</given-names></name><name><surname>Tynan</surname> <given-names>CJ</given-names></name><name><surname>Zanetti-Domingues</surname> <given-names>LC</given-names></name><name><surname>Kim</surname> <given-names>ET</given-names></name><name><surname>Losasso</surname> <given-names>V</given-names></name><name><surname>Korovesis</surname> <given-names>D</given-names></name><name><surname>Hirsch</surname> <given-names>M</given-names></name><name><surname>Rolfe</surname> <given-names>DJ</given-names></name><name><surname>Clarke</surname> <given-names>DT</given-names></name><name><surname>Winn</surname> <given-names>MD</given-names></name><name><surname>Lajevardipour</surname> <given-names>A</given-names></name><name><surname>Clayton</surname> <given-names>AHA</given-names></name><name><surname>Pike</surname> <given-names>LJ</given-names></name><name><surname>Perani</surname> <given-names>M</given-names></name><name><surname>Parker</surname> <given-names>PJ</given-names></name><name><surname>Shan</surname> <given-names>Y</given-names></name><name><surname>Shaw</surname> <given-names>DE</given-names></name><name><surname>Martin-Fernandez</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>EGFR oligomerization organizes kinase-active dimers into competent signalling platforms</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>13307</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms13307</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niesen</surname> <given-names>FH</given-names></name><name><surname>Berglund</surname> <given-names>H</given-names></name><name><surname>Vedadi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability</article-title><source>Nature Protocols</source><volume>2</volume><fpage>2212</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.321</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novotny</surname> <given-names>CJ</given-names></name><name><surname>Pollari</surname> <given-names>S</given-names></name><name><surname>Park</surname> <given-names>JH</given-names></name><name><surname>Lemmon</surname> <given-names>MA</given-names></name><name><surname>Shen</surname> <given-names>W</given-names></name><name><surname>Shokat</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Overcoming resistance to HER2 inhibitors through state-specific kinase binding</article-title><source>Nature Chemical Biology</source><volume>12</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2171</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogiso</surname> <given-names>H</given-names></name><name><surname>Ishitani</surname> <given-names>R</given-names></name><name><surname>Nureki</surname> <given-names>O</given-names></name><name><surname>Fukai</surname> <given-names>S</given-names></name><name><surname>Yamanaka</surname> <given-names>M</given-names></name><name><surname>Kim</surname> <given-names>J-H</given-names></name><name><surname>Saito</surname> <given-names>K</given-names></name><name><surname>Sakamoto</surname> <given-names>A</given-names></name><name><surname>Inoue</surname> <given-names>M</given-names></name><name><surname>Shirouzu</surname> <given-names>M</given-names></name><name><surname>Yokoyama</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains</article-title><source>Cell</source><volume>110</volume><fpage>775</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00963-7</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuzumi</surname> <given-names>T</given-names></name><name><surname>Fiedler</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Gray</surname> <given-names>DC</given-names></name><name><surname>Aizenstein</surname> <given-names>B</given-names></name><name><surname>Hoffman</surname> <given-names>R</given-names></name><name><surname>Shokat</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Inhibitor hijacking of Akt activation</article-title><source>Nature Chemical Biology</source><volume>5</volume><fpage>484</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1038/nchembio.183</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortiz-Zapater</surname> <given-names>E</given-names></name><name><surname>Lee</surname> <given-names>RW</given-names></name><name><surname>Owen</surname> <given-names>W</given-names></name><name><surname>Weitsman</surname> <given-names>G</given-names></name><name><surname>Fruhwirth</surname> <given-names>G</given-names></name><name><surname>Dunn</surname> <given-names>RG</given-names></name><name><surname>Neat</surname> <given-names>MJ</given-names></name><name><surname>McCaughan</surname> <given-names>F</given-names></name><name><surname>Parker</surname> <given-names>P</given-names></name><name><surname>Ng</surname> <given-names>T</given-names></name><name><surname>Santis</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition</article-title><source>PLoS One</source><volume>12</volume><fpage>e0170798</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0170798</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname> <given-names>MA</given-names></name><name><surname>Horten</surname> <given-names>BC</given-names></name><name><surname>Da Silva</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer Tissues</article-title><source>Clinical Breast Cancer</source><volume>5</volume><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.3816/CBC.2004.n.011</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papa</surname> <given-names>FR</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Shokat</surname> <given-names>KM</given-names></name><name><surname>Walter</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Bypassing a Kinase Activity with an ATP-Competitive Drug</article-title><source>Science</source><volume>302</volume><fpage>1533</fpage><lpage>1537</lpage><pub-id pub-id-type="doi">10.1126/science.1090031</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname> <given-names>M</given-names></name><name><surname>Ng</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Intracellular coupling of adhesion receptors: molecular proximity measurements</article-title><source>Methods in Cell Biology</source><volume>69</volume><fpage>261</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/S0091-679X(02)69017-X</pub-id><pub-id pub-id-type="pmid">12070997</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peter</surname> <given-names>M</given-names></name><name><surname>Ameer-Beg</surname> <given-names>SM</given-names></name><name><surname>Hughes</surname> <given-names>MKY</given-names></name><name><surname>Keppler</surname> <given-names>MD</given-names></name><name><surname>Prag</surname> <given-names>S</given-names></name><name><surname>Marsh</surname> <given-names>M</given-names></name><name><surname>Vojnovic</surname> <given-names>B</given-names></name><name><surname>Ng</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Multiphoton-FLIM Quantification of the EGFP-mRFP1 FRET Pair for Localization of Membrane Receptor-Kinase Interactions</article-title><source>Biophysical Journal</source><volume>88</volume><fpage>1224</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1529/biophysj.104.050153</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccart-Gebhart</surname> <given-names>M</given-names></name><name><surname>Holmes</surname> <given-names>E</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>de Azambuja</surname> <given-names>E</given-names></name><name><surname>Dueck</surname> <given-names>AC</given-names></name><name><surname>Viale</surname> <given-names>G</given-names></name><name><surname>Zujewski</surname> <given-names>JA</given-names></name><name><surname>Goldhirsch</surname> <given-names>A</given-names></name><name><surname>Armour</surname> <given-names>A</given-names></name><name><surname>Pritchard</surname> <given-names>KI</given-names></name><name><surname>McCullough</surname> <given-names>AE</given-names></name><name><surname>Dolci</surname> <given-names>S</given-names></name><name><surname>McFadden</surname> <given-names>E</given-names></name><name><surname>Holmes</surname> <given-names>AP</given-names></name><name><surname>Tonghua</surname> <given-names>L</given-names></name><name><surname>Eidtmann</surname> <given-names>H</given-names></name><name><surname>Dinh</surname> <given-names>P</given-names></name><name><surname>Di Cosimo</surname> <given-names>S</given-names></name><name><surname>Harbeck</surname> <given-names>N</given-names></name><name><surname>Tjulandin</surname> <given-names>S</given-names></name><name><surname>Im</surname> <given-names>Y-H</given-names></name><name><surname>Huang</surname> <given-names>C-S</given-names></name><name><surname>Diéras</surname> <given-names>V</given-names></name><name><surname>Hillman</surname> <given-names>DW</given-names></name><name><surname>Wolff</surname> <given-names>AC</given-names></name><name><surname>Jackisch</surname> <given-names>C</given-names></name><name><surname>Lang</surname> <given-names>I</given-names></name><name><surname>Untch</surname> <given-names>M</given-names></name><name><surname>Smith</surname> <given-names>I</given-names></name><name><surname>Boyle</surname> <given-names>F</given-names></name><name><surname>Xu</surname> <given-names>B</given-names></name><name><surname>Gomez</surname> <given-names>H</given-names></name><name><surname>Suter</surname> <given-names>T</given-names></name><name><surname>Gelber</surname> <given-names>RD</given-names></name><name><surname>Perez</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial</article-title><source>Journal of Clinical Oncology</source><volume>34</volume><fpage>1034</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.62.1797</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulikakos</surname> <given-names>PI</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Bollag</surname> <given-names>G</given-names></name><name><surname>Shokat</surname> <given-names>KM</given-names></name><name><surname>Rosen</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</article-title><source>Nature</source><volume>464</volume><fpage>427</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/nature08902</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradeep</surname> <given-names>S</given-names></name><name><surname>Kim</surname> <given-names>SW</given-names></name><name><surname>Wu</surname> <given-names>SY</given-names></name><name><surname>Nishimura</surname> <given-names>M</given-names></name><name><surname>Chaluvally-Raghavan</surname> <given-names>P</given-names></name><name><surname>Miyake</surname> <given-names>T</given-names></name><name><surname>Pecot</surname> <given-names>CV</given-names></name><name><surname>Kim</surname> <given-names>S-J</given-names></name><name><surname>Choi</surname> <given-names>HJ</given-names></name><name><surname>Bischoff</surname> <given-names>FZ</given-names></name><name><surname>Mayer</surname> <given-names>JA</given-names></name><name><surname>Huang</surname> <given-names>L</given-names></name><name><surname>Nick</surname> <given-names>AM</given-names></name><name><surname>Hall</surname> <given-names>CS</given-names></name><name><surname>Rodriguez-Aguayo</surname> <given-names>C</given-names></name><name><surname>Zand</surname> <given-names>B</given-names></name><name><surname>Dalton</surname> <given-names>HJ</given-names></name><name><surname>Arumugam</surname> <given-names>T</given-names></name><name><surname>Lee</surname> <given-names>HJ</given-names></name><name><surname>Han</surname> <given-names>HD</given-names></name><name><surname>Cho</surname> <given-names>MS</given-names></name><name><surname>Rupaimoole</surname> <given-names>R</given-names></name><name><surname>Mangala</surname> <given-names>LS</given-names></name><name><surname>Sehgal</surname> <given-names>V</given-names></name><name><surname>Oh</surname> <given-names>SC</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Lee</surname> <given-names>J-S</given-names></name><name><surname>Coleman</surname> <given-names>RL</given-names></name><name><surname>Ram</surname> <given-names>P</given-names></name><name><surname>Lopez-Berestein</surname> <given-names>G</given-names></name><name><surname>Fidler</surname> <given-names>IJ</given-names></name><name><surname>Sood</surname> <given-names>AK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread</article-title><source>Cancer Cell</source><volume>26</volume><fpage>77</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.05.002</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinhard</surname> <given-names>FBM</given-names></name><name><surname>Eberhard</surname> <given-names>D</given-names></name><name><surname>Werner</surname> <given-names>T</given-names></name><name><surname>Franken</surname> <given-names>H</given-names></name><name><surname>Childs</surname> <given-names>D</given-names></name><name><surname>Doce</surname> <given-names>C</given-names></name><name><surname>Savitski</surname> <given-names>MF</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name><name><surname>Bantscheff</surname> <given-names>M</given-names></name><name><surname>Savitski</surname> <given-names>MM</given-names></name><name><surname>Drewes</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Thermal proteome profiling monitors ligand interactions with cellular membrane proteins</article-title><source>Nature Methods</source><volume>12</volume><fpage>1129</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3652</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname> <given-names>FA</given-names></name><name><surname>Hawley</surname> <given-names>SA</given-names></name><name><surname>Auciello</surname> <given-names>FR</given-names></name><name><surname>Gowans</surname> <given-names>GJ</given-names></name><name><surname>Atrih</surname> <given-names>A</given-names></name><name><surname>Lamont</surname> <given-names>DJ</given-names></name><name><surname>Hardie</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mechanisms of Paradoxical Activation of AMPK by the Kinase Inhibitors SU6656 and Sorafenib</article-title><source>Cell Chemical Biology</source><volume>24</volume><fpage>813</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2017.05.021</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin-Delanchy</surname> <given-names>P</given-names></name><name><surname>Burn</surname> <given-names>GL</given-names></name><name><surname>Griffié</surname> <given-names>J</given-names></name><name><surname>Williamson</surname> <given-names>DJ</given-names></name><name><surname>Heard</surname> <given-names>NA</given-names></name><name><surname>Cope</surname> <given-names>AP</given-names></name><name><surname>Owen</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bayesian cluster identification in single-molecule localization microscopy data</article-title><source>Nature Methods</source><volume>12</volume><fpage>1072</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3612</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saffarian</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Elson</surname> <given-names>EL</given-names></name><name><surname>Pike</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Oligomerization of the EGF receptor investigated by live cell fluorescence intensity distribution analysis</article-title><source>Biophysical Journal</source><volume>93</volume><fpage>1021</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1529/biophysj.107.105494</pub-id><pub-id pub-id-type="pmid">17496034</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sali</surname> <given-names>A</given-names></name><name><surname>Blundell</surname> <given-names>TL</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Comparative protein modelling by satisfaction of spatial restraints</article-title><source>Journal of Molecular Biology</source><volume>234</volume><fpage>779</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1993.1626</pub-id><pub-id pub-id-type="pmid">8254673</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheeff</surname> <given-names>ED</given-names></name><name><surname>Eswaran</surname> <given-names>J</given-names></name><name><surname>Bunkoczi</surname> <given-names>G</given-names></name><name><surname>Knapp</surname> <given-names>S</given-names></name><name><surname>Manning</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site</article-title><source>Structure</source><volume>17</volume><fpage>128</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.str.2008.10.018</pub-id><pub-id pub-id-type="pmid">19141289</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sergina</surname> <given-names>NV</given-names></name><name><surname>Rausch</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Blair</surname> <given-names>J</given-names></name><name><surname>Hann</surname> <given-names>B</given-names></name><name><surname>Shokat</surname> <given-names>KM</given-names></name><name><surname>Moasser</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3</article-title><source>Nature</source><volume>445</volume><fpage>437</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1038/nature05474</pub-id><pub-id pub-id-type="pmid">17206155</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>F</given-names></name><name><surname>Telesco</surname> <given-names>SE</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Radhakrishnan</surname> <given-names>R</given-names></name><name><surname>Lemmon</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation</article-title><source>PNAS</source><volume>107</volume><fpage>7692</fpage><lpage>7697</lpage><pub-id pub-id-type="doi">10.1073/pnas.1002753107</pub-id><pub-id pub-id-type="pmid">20351256</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simossis</surname> <given-names>VA</given-names></name><name><surname>Kleinjung</surname> <given-names>J</given-names></name><name><surname>Heringa</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Homology-extended sequence alignment</article-title><source>Nucleic Acids Research</source><volume>33</volume><fpage>816</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1093/nar/gki233</pub-id><pub-id pub-id-type="pmid">15699183</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slamon</surname> <given-names>DJ</given-names></name><name><surname>Clark</surname> <given-names>GM</given-names></name><name><surname>Wong</surname> <given-names>SG</given-names></name><name><surname>Levin</surname> <given-names>WJ</given-names></name><name><surname>Ullrich</surname> <given-names>A</given-names></name><name><surname>McGuire</surname> <given-names>WL</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene</article-title><source>Science</source><volume>235</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1126/science.3798106</pub-id><pub-id pub-id-type="pmid">3798106</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sliwkowski</surname> <given-names>MX</given-names></name><name><surname>Schaefer</surname> <given-names>G</given-names></name><name><surname>Akita</surname> <given-names>RW</given-names></name><name><surname>Lofgren</surname> <given-names>JA</given-names></name><name><surname>Fitzpatrick</surname> <given-names>VD</given-names></name><name><surname>Nuijens</surname> <given-names>A</given-names></name><name><surname>Fendly</surname> <given-names>BM</given-names></name><name><surname>Cerione</surname> <given-names>RA</given-names></name><name><surname>Vandlen</surname> <given-names>RL</given-names></name><name><surname>Carraway</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin</article-title><source>The Journal of Biological Chemistry</source><volume>269</volume><fpage>14661</fpage><lpage>14665</lpage><pub-id pub-id-type="pmid">7514177</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thevakumaran</surname> <given-names>N</given-names></name><name><surname>Lavoie</surname> <given-names>H</given-names></name><name><surname>Critton</surname> <given-names>DA</given-names></name><name><surname>Tebben</surname> <given-names>A</given-names></name><name><surname>Marinier</surname> <given-names>A</given-names></name><name><surname>Sicheri</surname> <given-names>F</given-names></name><name><surname>Therrien</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>22</volume><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2924</pub-id><pub-id pub-id-type="pmid">25437913</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiel</surname> <given-names>KW</given-names></name><name><surname>Carpenter</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation</article-title><source>PNAS</source><volume>104</volume><fpage>19238</fpage><lpage>19243</lpage><pub-id pub-id-type="doi">10.1073/pnas.0703854104</pub-id><pub-id pub-id-type="pmid">18042729</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Lengerich</surname> <given-names>B</given-names></name><name><surname>Agnew</surname> <given-names>C</given-names></name><name><surname>Puchner</surname> <given-names>EM</given-names></name><name><surname>Huang</surname> <given-names>B</given-names></name><name><surname>Jura</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms</article-title><source>PNAS</source><volume>114</volume><fpage>E2836</fpage><lpage>E2845</lpage><pub-id pub-id-type="doi">10.1073/pnas.1617994114</pub-id><pub-id pub-id-type="pmid">28320942</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Perera</surname> <given-names>BG</given-names></name><name><surname>Hari</surname> <given-names>SB</given-names></name><name><surname>Bhhatarai</surname> <given-names>B</given-names></name><name><surname>Backes</surname> <given-names>BJ</given-names></name><name><surname>Seeliger</surname> <given-names>MA</given-names></name><name><surname>Schürer</surname> <given-names>SC</given-names></name><name><surname>Oakes</surname> <given-names>SA</given-names></name><name><surname>Papa</surname> <given-names>FR</given-names></name><name><surname>Maly</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors</article-title><source>Nature Chemical Biology</source><volume>8</volume><fpage>982</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1094</pub-id><pub-id pub-id-type="pmid">23086298</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname> <given-names>TR</given-names></name><name><surname>Fridlyand</surname> <given-names>J</given-names></name><name><surname>Yan</surname> <given-names>Y</given-names></name><name><surname>Penuel</surname> <given-names>E</given-names></name><name><surname>Burton</surname> <given-names>L</given-names></name><name><surname>Chan</surname> <given-names>E</given-names></name><name><surname>Peng</surname> <given-names>J</given-names></name><name><surname>Lin</surname> <given-names>E</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Sosman</surname> <given-names>J</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Moffat</surname> <given-names>J</given-names></name><name><surname>Sutherlin</surname> <given-names>DP</given-names></name><name><surname>Koeppen</surname> <given-names>H</given-names></name><name><surname>Merchant</surname> <given-names>M</given-names></name><name><surname>Neve</surname> <given-names>R</given-names></name><name><surname>Settleman</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors</article-title><source>Nature</source><volume>487</volume><fpage>505</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1038/nature11249</pub-id><pub-id pub-id-type="pmid">22763448</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname> <given-names>ER</given-names></name><name><surname>Truesdale</surname> <given-names>AT</given-names></name><name><surname>McDonald</surname> <given-names>OB</given-names></name><name><surname>Yuan</surname> <given-names>D</given-names></name><name><surname>Hassell</surname> <given-names>A</given-names></name><name><surname>Dickerson</surname> <given-names>SH</given-names></name><name><surname>Ellis</surname> <given-names>B</given-names></name><name><surname>Pennisi</surname> <given-names>C</given-names></name><name><surname>Horne</surname> <given-names>E</given-names></name><name><surname>Lackey</surname> <given-names>K</given-names></name><name><surname>Alligood</surname> <given-names>KJ</given-names></name><name><surname>Rusnak</surname> <given-names>DW</given-names></name><name><surname>Gilmer</surname> <given-names>TM</given-names></name><name><surname>Shewchuk</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</article-title><source>Cancer Research</source><volume>64</volume><fpage>6652</fpage><lpage>6659</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1168</pub-id><pub-id pub-id-type="pmid">15374980</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname> <given-names>W</given-names></name><name><surname>Petricoin</surname> <given-names>EF</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Osada</surname> <given-names>T</given-names></name><name><surname>Cheng</surname> <given-names>Q</given-names></name><name><surname>Wulfkuhle</surname> <given-names>JD</given-names></name><name><surname>Gwin</surname> <given-names>WR</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name><name><surname>Gallagher</surname> <given-names>RI</given-names></name><name><surname>Bacus</surname> <given-names>S</given-names></name><name><surname>Lyerly</surname> <given-names>HK</given-names></name><name><surname>Spector</surname> <given-names>NL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models</article-title><source>Breast Cancer Research</source><volume>15</volume><elocation-id>R85</elocation-id><pub-id pub-id-type="doi">10.1186/bcr3480</pub-id><pub-id pub-id-type="pmid">24044505</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname> <given-names>T</given-names></name><name><surname>Lim</surname> <given-names>SM</given-names></name><name><surname>Westover</surname> <given-names>KD</given-names></name><name><surname>Dodge</surname> <given-names>ME</given-names></name><name><surname>Ercan</surname> <given-names>D</given-names></name><name><surname>Ficarro</surname> <given-names>SB</given-names></name><name><surname>Udayakumar</surname> <given-names>D</given-names></name><name><surname>Gurbani</surname> <given-names>D</given-names></name><name><surname>Tae</surname> <given-names>HS</given-names></name><name><surname>Riddle</surname> <given-names>SM</given-names></name><name><surname>Sim</surname> <given-names>T</given-names></name><name><surname>Marto</surname> <given-names>JA</given-names></name><name><surname>Jänne</surname> <given-names>PA</given-names></name><name><surname>Crews</surname> <given-names>CM</given-names></name><name><surname>Gray</surname> <given-names>NS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pharmacological targeting of the pseudokinase Her3</article-title><source>Nature Chemical Biology</source><volume>10</volume><fpage>1006</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1658</pub-id><pub-id pub-id-type="pmid">25326665</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>S</given-names></name><name><surname>Raymond-Stintz</surname> <given-names>MA</given-names></name><name><surname>Ying</surname> <given-names>W</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Lidke</surname> <given-names>DS</given-names></name><name><surname>Steinberg</surname> <given-names>SL</given-names></name><name><surname>Williams</surname> <given-names>L</given-names></name><name><surname>Oliver</surname> <given-names>JM</given-names></name><name><surname>Wilson</surname> <given-names>BS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mapping ErbB receptors on breast cancer cell membranes during signal transduction</article-title><source>Journal of Cell Science</source><volume>120</volume><fpage>2763</fpage><lpage>2773</lpage><pub-id pub-id-type="doi">10.1242/jcs.007658</pub-id><pub-id pub-id-type="pmid">17652160</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarden</surname> <given-names>Y</given-names></name><name><surname>Pines</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The ERBB network: at last, cancer therapy meets systems biology</article-title><source>Nature Reviews Cancer</source><volume>12</volume><fpage>553</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/nrc3309</pub-id><pub-id pub-id-type="pmid">22785351</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeqiraj</surname> <given-names>E</given-names></name><name><surname>Filippi</surname> <given-names>BM</given-names></name><name><surname>Deak</surname> <given-names>M</given-names></name><name><surname>Alessi</surname> <given-names>DR</given-names></name><name><surname>van Aalten</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2009">2009a</year><article-title>Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation</article-title><source>Science</source><volume>326</volume><fpage>1707</fpage><lpage>1711</lpage><pub-id pub-id-type="doi">10.1126/science.1178377</pub-id><pub-id pub-id-type="pmid">19892943</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeqiraj</surname> <given-names>E</given-names></name><name><surname>Filippi</surname> <given-names>BM</given-names></name><name><surname>Goldie</surname> <given-names>S</given-names></name><name><surname>Navratilova</surname> <given-names>I</given-names></name><name><surname>Boudeau</surname> <given-names>J</given-names></name><name><surname>Deak</surname> <given-names>M</given-names></name><name><surname>Alessi</surname> <given-names>DR</given-names></name><name><surname>van Aalten</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2009">2009b</year><article-title>ATP and MO25alpha regulate the conformational state of the STRADalpha pseudokinase and activation of the LKB1 tumour suppressor</article-title><source>PLoS Biology</source><volume>7</volume><elocation-id>e1000126</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1000126</pub-id><pub-id pub-id-type="pmid">19513107</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>R</given-names></name><name><surname>Fruhwirth</surname> <given-names>GO</given-names></name><name><surname>Coban</surname> <given-names>O</given-names></name><name><surname>Barrett</surname> <given-names>JE</given-names></name><name><surname>Burgoyne</surname> <given-names>T</given-names></name><name><surname>Lee</surname> <given-names>SH</given-names></name><name><surname>Simonson</surname> <given-names>PD</given-names></name><name><surname>Baday</surname> <given-names>M</given-names></name><name><surname>Kholodenko</surname> <given-names>BN</given-names></name><name><surname>Futter</surname> <given-names>CE</given-names></name><name><surname>Ng</surname> <given-names>T</given-names></name><name><surname>Selvin</surname> <given-names>PR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Probing the heterogeneity of protein kinase activation in cells by super-resolution microscopy</article-title><source>ACS Nano</source><volume>11</volume><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1021/acsnano.6b05356</pub-id><pub-id pub-id-type="pmid">27768850</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Gureasko</surname> <given-names>J</given-names></name><name><surname>Shen</surname> <given-names>K</given-names></name><name><surname>Cole</surname> <given-names>PA</given-names></name><name><surname>Kuriyan</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</article-title><source>Cell</source><volume>125</volume><fpage>1137</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.05.013</pub-id><pub-id pub-id-type="pmid">16777603</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.32271.036</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Cravatt</surname><given-names>Benjamin F</given-names></name><role>Reviewing Editor</role><aff id="aff15"><institution>The Scripps Research Institute</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jonathan Cooper as the Senior Editor. The following individual involved in review of your submission has agreed to reveal his identity: Nathanael S Gray (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>The reviewers were generally quite impressed by the manuscript, noting that it represented a very nice molecular pharmacology detective story to try to explain the paradoxical activation of Her2 signaling upon treatment with an ATP-competitive Her2 inhibitor Lapatinib. Key observations supported by the data presented include 1) the Her2/Her3 dimer induced by lapatinib + neuregulin does not resemble the head to tail model for &quot;normal&quot; activation by neuregulin alone, but a head to head orientation, previously only observed in the HER3 crystal structure 2) the Her3 ATP site needs to be occupied by a ligand (ATP or bosutinib) for the hyperactivation to occur, 3) an irreversible version of lapatinib (neratinib) does not activate cell growth – presumably because the compound is irreversibly bound to HER2. The reviewers felt that these observations are an important contribution to our understanding of HER2/HER3 signaling in breast cancer. However, several points were raised for revision, including some that will require additional experiments.</p><p>Essential revisions:</p><p>1) The authors use various mutations in Her3 to show ATP binding by Her3 is important to maintain activating ability of lapatinib. They should show CETSA or other binding data for what these mutations do to bosutinib affinity of Her3 in cells. Also I wondered what bosutinib combined with lapatinib does in the presence of these mutations (synergy or antagonism and do the mutations abrogate this effect)? The authors could also have used the covalent Her3 binder TX1-85-1 (Nat Chem Biol. 2014 Dec; 10(12): 1006-1012.) which is more selective than bosutinib as a way to interrogate what Her3 ATP-site ligation does to the pharmacology of lapatinib.</p><p>2) Much of the mechanistic analysis is done in SKBR3 cells, which from the data presented appear to be somewhat of an outlier in terms of the Neuregulin + lapatinib induction of growth. In Figure 1—figure supplement 1 the authors investigate three other cells, BT474, MCF7, and ZR75. The first is a high Her2 expresser and also shows the same Neuregulin + lapatinib enhanced growth. Several more HER2 overexpressing cell lines should be tested for this effect (2-5 should suffice).</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.32271.037</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The authors use various mutations in Her3 to show ATP binding by Her3 is important to maintain activating ability of lapatinib. They should show CETSA or other binding data for what these mutations do to bosutinib affinity of Her3 in cells. Also I wondered what bosutinib combined with lapatinib does in the presence of these mutations (synergy or antagonism and do the mutations abrogate this effect)? The authors could also have used the covalent Her3 binder TX1-85-1 (Nat Chem Biol. 2014 Dec; 10(12): 1006-1012.) which is more selective than bosutinib as a way to interrogate what Her3 ATP-site ligation does to the pharmacology of lapatinib.</p></disp-quote><p>Based on the reviewer’s suggestions we have included CETSA binding data of COS7 cells transfected with HER3<sup>wt</sup>, HER3<sup>KGG</sup> or the bosutinib-desensitised mutation HER3<sup>T787M</sup>. We compared the recovery of HER3 protein between 44°C and 50°C in the presence or absence of bosutinib and show that bosutinib stabilises HER3<sup>wt</sup>, but it does not stabilise either the HER3<sup>KGG</sup> or HER3<sup>T787M</sup> mutations. This corresponds to our proliferation data to suggest that HER3<sup>KGG</sup> does not have strong affinity for bosutinib in cells. This data is included in the revised manuscript as Figure 2—figure supplement 1G.</p><p>The reviewers suggest the use of the covalent HER3 inhibitor TX1-85-1 as a more selective inhibitor than bosutinib. In the original publication cited (Xie et al., 2014) the authors demonstrate TX1-85-1 potently inhibits HER2 (Supplementary Table 1 in Xie et al.). Although the covalent binding to HER3 would make TX1-85-1 an interesting tool to probe ATP-binding pocket behaviour in HER3, the fact that it is also a potent HER2 binder would confound the analysis in the proposed assays.</p><p>HER3 has been reported to be the only EGFR family member that tightly binds bosutinib due to an alanine equivalent to Src<sup>A403</sup>, which is lacking in other EGFR family members (Levinson et al. Nat Chem Biol 2013, DOI 10.1038/NCHEMBIO.1404). This is supported by screening data from Davis et al., 2011. To verify, we have included <italic>in vitro</italic> TSA analysis of HER2 kinase domain treated with Mg<sup>2+</sup>/ATP, lapatinib or bosutinib. This data agrees with the published results on HER2-bosutinib binding, showing that HER2 is not a strong binder of bosutinib in our hands. This data is included in the revised manuscript as Figure 2B.</p><disp-quote content-type="editor-comment"><p>2) Much of the mechanistic analysis is done in SKBR3 cells, which from the data presented appear to be somewhat of an outlier in terms of the Neuregulin + lapatinib induction of growth. In Figure 1—figure supplement 1 the authors investigate three other cells, BT474, MCF7, and ZR75. The first is a high Her2 expresser and also shows the same Neuregulin + lapatinib enhanced growth. Several more HER2 overexpressing cell lines should be tested for this effect (2-5 should suffice).</p></disp-quote><p>As the reviewers suggested, we have included additional cell lines in the revised manuscript and reclassified the presentation of the various cell lines in Figure 1—figure supplement 1. Instead of referring to the HER2 expressions status, we present the data as ‘lapatinib-responding’, ‘partial lapatinib response’ and ‘lapatinib non-responding’, based on the cellular toxicity presented by lapatinib. We match the phenotype seen in SKBR3 with BT474 and AU565, show a partial match with ZR75 and HCC1419, and a negative response with MCF7 and HCC1569.</p></body></sub-article></article>